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 Protein therapeutics have emerged as potent and highly specific treatment options 
offering many advantages over small molecule drugs. Many protein therapeutics currently target 
extracellular secreted cytokines or receptors on the cell membrane. There is a trove of druggable 
targets that reside within the cell. Pathogens such as Salmonella target these intracellular 
moieties via bacterial effector enzymes to promote its own survival and replication. These 
enzymes are the product of evolution and have the ability to modulate immune function by 
modifying key proteins along eukaryotic inflammatory and apoptotic signaling pathways. 
Utilizing these enzymes in the absence of Salmonella can provide a unique opportunity to treat 
chronic inflammation such as in inflammatory bowel disease. A major challenge to realizing 
enzymes with intracellular activity as therapies is delivery into cells. Salmonella utilizes a 
needle-like structure that can penetrate the cell membrane to gain access to the cytosol. Without 
this delivery mechanism, an alternative delivery system must be engineered. 
 To address this challenge, we engineered a protein nanoparticles (NPs) containing an 
anti-inflammatory and anti-apoptotic Salmonella enzyme with intracellular activity, AvrA. 
Unlike traditional NP carriers commonly used to deliver drugs, protein NPs have 
biodegradability into amino acids.  These NPs are synthesized by desolvating a solution of 
soluble protein and stabilizing the nanoclusters with a reducible crosslinker designed to break 
apart in the reducing environment of the cytosol. Protein NPs exhibit enhanced cellular uptake 
and internalization compared to soluble protein, and protein NPs maintain AvrA enzymatic 
function after delivery to cells. Our results show that AvrA NP formulations are internalized by 
barrier epithelial and immune cells, inhibiting the inflammatory signaling and conferring 




clinical and histological scores of inflammation. Overall, AvrA NPs highlight the potential of 
protein NPs as delivery vehicles and therapeutics to treat inflammatory bowel disease.  
 Transrectally delivery is undesirable for patients and also limits delivery to the distal 
portion of the colon, both of which hinder the clinical potential of AvrA NPs. Therefore, we 
sought to engineer an oral delivery vehicle to maximize therapeutic potential. The biggest 
obstacle to oral delivery of proteins is the harsh environment found in the stomach, where low 
pH, digestive enzymes, and mechanical forces act to break down proteinaceous materials for 
digestion. We engineered alginate/chitosan hydrogel microparticles (MPs) encapsulating AvrA 
NPs using a flow focusing microfluidic device for the gastric passage and intestinal release of 
AvrA NPs. Alginate and chitosan are two naturally derived polysaccharides generally regarded 
as safe by the FDA. Alginate hydrogels can encapsulate AvrA NPs under mild conditions and 
exhibit pH responsivity, preventing release in the stomach and allowing NPs to release in the 
intestine. We show that coating alginate MPs with chitosan increases NP encapsulation 
efficiency and improves retention of bioactive protein NPs after gastric incubation. Oral gavage 
of AvrA NPs encapsulated in alginate/chitosan MPs reduced clinical and histological scores of 
inflammation in a colitis mouse model.  
 Though we have shown the ability of protein NPs to deliver enzymes to the cytosol of 
cells, NP delivery vehicles in general suffer from endosomal entrapment that results in low 
cytosolic delivery efficiency. Achieving endosomal escape is highly desirable and understanding 
how cells traffic endosomes can provide insight how to avoid lysosomal degradation. NPs, once 
administrated in vivo, encounter a milieu of serum proteins mainly in the blood. The adsorption 
of serum proteins onto NPs, called the protein corona, can modify the NP’s physiochemical 




understand protein corona formation around protein NPs, we synthesized various protein NPs 
with different physiochemical properties. We find that properties of the carrier protein govern the 
properties of the protein NPs after desolvation and observes qualitative differences in the protein 
corona that forms around protein NPs compared to traditional polymeric NPs. 
This thesis focuses on using naturally derived materials as building blocks for drug 
delivery vehicles and reengineering the tools used by pathogenic bacteria for therapeutic 
purposes. The protein NP platform and encapsulation with alginate/chitosan MPs is generalizable 
to other therapeutic proteins. Incorporating multiple therapeutic proteins into a single protein NP 
delivery vehicle can combat diseases through multiple modes of action leading to a highly 
effective treatment. The alginate/chitosan MP oral delivery platform can accommodate protein 
therapeutics, probiotics, and other macromolecules to protect from the harsh conditions of the 
stomach and released in the intestines. Overall, these results show the clinical potential of 
implementing protein NPs as intracellular therapeutics and provides an oral delivery platform to 
do so. Further, we show the ability to control protein NP properties through choice of carrier 











CHAPTER 1 : Introduction 
 
 
1.1 Inflammatory Bowel Disease 
Crohn’s disease (CD) and ulcerative colitis (UC), the two major forms of inflammatory 
bowel disease (IBD), are chronic inflammatory disorders of the gastrointestinal tract resulting 
from inappropriate and amplified mucosal immune responses to the otherwise normal microbiota 
existing in the gut1, 2, 3. The CDC estimates that approximately 3.1 million people in the US are 
living with IBD4 and there is an increasing global prevalence5, 6of the disease. The growing 
incidence of IBD in a relatively short duration of human generations indicates that genetic 
factors alone are unlikely to explain the pathology. Microbiota coexisting with our gut have 
substantially shorter generation times making it susceptible to rapid evolutionary changes from 
the environment such as infection, hygiene, diet, and medication. Whether environmental 
selection pressures produce a pathogenic microbiome, also called dysbiosis, or if dysbiosis is a 
consequence of the altered intestinal environment in IBD patients is still unknown3. IBD patients 
have depletion of commensal bacteria resulting in decreased microbial richness7, increased 
epithelial permeability allowing increased bacterial translocation8. Other mechanisms such as 
microbial sensing, antigen processing, and oxygen level can also contribute to loss of intestinal 
function. The unknown pathology of IBD has led to complicated treatment regimens. Patients 
use a combination of locally acting anti-inflammatory small molecules9, 10, 11, systemic 
corticosteroids, monoclonal antibodies12, and surgery. Although these treatments can be effective 
for many patients, they have specific windows of efficacy10, long-term side effects13, 14, 15, and 




monitoring is essential. This includes colon cancer surveillance and continual assessment of 
remission maintenance drugs every 6-12 months17. 
The primary therapeutic goals for patients with IBD is prevention of ulcerations in the 
gastrointestinal tract and maintenance of this remission long term. Endoscopic or mucosal 
healing improves long-term clinical remission and is correlated with reduced relapse rates, need 
for surgery, and cessation of rectal bleeding18. This state of remission also means that a patient is 
less likely to develop more serious associated symptoms such as colorectal cancer. The first line 
of defense for patients with mild to moderate symptoms of IBD is small molecule anti-
inflammatory, 5-aminosalicylates. If successful, 5-aminosalicylates are also typically given to 
maintain remission meaning that a patient is likely to continually rely on this medication. If 
ineffective, the next line of treatment is systemic corticosteroids. Corticosteroids are only used 
for treatment of the disease and cannot be used for maintenance of remission due to ineffective 
long-term efficacy and risk of side effects19. Patients can become steroid dependent20 and in 
some cases steroid withdrawal needs to be closely monitored because prolonged exposure is 
associated with diabetes, bone loss, hypertension, and infections21. More serious cases of 
gastrointestinal inflammation rely on stronger immunosuppressing chemotherapies such as 
thiopurines and methotrexate. Though these have more serious side effects such as lymphoma, 
they are only associated with modest efficacy rates17, 21.  
More recently, monoclonal anti-TNF-α antibodies have been shown to be effective in 
inducing and maintaining remission. TNF-α inhibitors are a popular approach to combating other 
autoimmune diseases such as rheumatoid arthritis and immune-related skin diseases such as 
psoriasis. They have also been shown to be potent agents to induce remission in IBD, however, 




or immunosuppressants. Therefore, anti-TNF-α therapies is used in combination with 5-
aminosalicylates, corticosteroids, and immunosuppressants for the maintenance of remission as 
well. This combinatory usage have also been associated with increased risk of opportunistic 
infections22, melanoma skin cancer23, and lymphoma14. Monoclonal antibodies also have the 
potential to develop immunogenicity meaning they lose their efficacy over time24 requiring 
higher dosages and potentially increasing systemic effects.  
Another monoclonal antibody that blocks a4b7 integrin is now available as a gut-
selective anti-inflammatory25, which prevents activated T-cells from adhering to the gut 
endothelium and eventual extravasation into gut mucosal tissue. There have also been other 
monoclonal antibodies that focus on neutralizing the p40 subunit common on both IL-12 and IL-
2326. These two cytokines are overexpressed in patients with IBD and are believed to perpetuate 
a chronic inflammatory state by continually stimulating T-cells. Due to the novelty of these new 
therapies and lack of long-term safety studies, they are reserved for patients where anti-TNF-α 
treatment has failed21. In the most serious cases, where none of the above treatments are effective 
in inducing remission, surgery is necessary to relieve abscesses and malignancies. Surgery is not 
a cure however, as relapses can still occur17, 21. 
Current clinical trials are testing other anti-adhesion targets such as antibodies blocking 
cell adhesion molecule (CAM) proteins21 on gut endothelial tissue. Small molecule janus kinase 
(JAK) inhibitors are also being explored27. The JAK family of tyrosine kinases controls many 
intracellular signaling pathways resulting in inflammatory cytokine production. An 
oligonucleotide siRNA that silences SMAD7 is also being investigated28. SMAD7 is a TGF-b1 
antagonist and restoring TGF-b1 activity leads to suppression of pro-inflammatory cytokines 




to work, the SMAD7 siRNA must achieve intracellular cytosolic delivery where the mRNA 
substrate is available. Whereas more traditional IBD therapies target secreted cytokines from 
immune cells or cell surface markers found on T-cells, emerging therapies target intracellular 
components. Development of JAK inhibitors and SMAD7 siRNA is a shift in IBD strategy to 
realize the potential of intracellular drug targets. New treatments should also focus on 
modulating the innate and adaptive immune system to stop the perpetuation of chronic 




1.2 Bacterial Effector Protein, AvrA 
Areas of chronic gut inflammation are driven by hyper reactive autoimmune cells 
producing inflammatory cytokines in response to external stimuli. Cells react to these cytokines 
through receptor-mediated intracellular signaling pathways ultimately leading to a transcriptional 
response in the nucleus. Inflammatory cytokines can activate two major intracellular signaling 
highways, the mitogen-activated protein kinase (MAPK) c-Jun N-terminal kinase (JNK)29, 30, 31 
and/or nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kb)32, 33, 34 pathways, 
which control innate immunity, cell growth, proliferation, survival, and death. Enteric pathogenic 
bacteria have evolved mechanisms that can modulate these intracellular inflammatory and 
immunoregulatory pathways35, 36, 37 by injecting bacterial effector proteins via a needle-like type-
3 secretion system (T3SS). The most studied gram-negative bacterial pathogenic species 
Escherichia, Yersinia, Shigella, and Salmonella all utilize a conserved T3SS38 to deliver their 




evolved unique mechanisms to manipulate host immune response, cytoskeletal dynamics, vesicle 
transport and signal transduction pathways for survival.  
One of these bacterial effector proteins, AvrA derived from Salmonella39, 40, 41, is a 
member of a family of acetyltransferases that covalently modify and inactivate members of the 
MAPK superfamily42. AvrA is found on Salmonella pathogenicity island 1 (SPI-1), a cluster of 
genes acquired through horizontal transfer43. SPI-1 genes are activated and secreted early in 
infection to promote bacterial internalization and Salmonella-containing vacuole (SCV) 
biogenesis. AvrA is believed to be secreted into the cytoplasm by a T3SS once a SCV is formed 
to help dampen host immune response and inhibit apoptosis44. SCVs are able to recruit nutrient-
rich host vesicles to fuse with, allowing Salmonella replication within a maturing SCV45. After 
SCV maturation and bacterial replication begins, SPI-2 is activated to inhibit lysosomal 
maturation and apoptosis. SPI-2 also help direct the SCV to the perinuclear region close to the 
endoplasmic reticulum and promote the formation vacuole-associated actin polymerization 
(VAP) to stabilize the SCV. Despite differences in temporal activation of the two SPIs, the two 
islands are closely linked as several effector proteins are found on both46. 
Identifying and isolating specific effector proteins involved during bacterial infection 
reveals a unique trove of potential therapeutic drugs. AvrA overexpressed in transfected cells41 
or in a Drosophila transgenic model47 blocked activation of NF-κB,  JNK MAPK, and 
transcriptional activation of a range of inflammatory effector genes. Specifically, AvrA is 
capable of acetylating key serine and threonine residues on MKK4/7 thus inhibiting 
phosphorylation of these upstream JNK signaling pathway and blocking apoptosis47, 48, 49. 
Similar results were demonstrated in a yeast model48 as well. AvrA has also been shown to 




acetyltransferase activity, it has also been reported that AvrA indirectly deubiquitinates Iκβα by 
an unknown mechanism, stabilizing phosphorylated-Iκβα (p-Iκβα) and inhibiting further 
phosphorylation, thereby preventing transcription of NF-kb41, 51. AvrA’s ability to inhibit stress 
signaling pathways without inducing apoptosis is reported in yeast, flies, human, and murine 
intestinal epithelial41, 42, 47, 48. This evolved bacterial protein with combined anti-inflammatory 
and anti-apoptotic enzymatic functions make it an ideal therapeutic to ameliorate IBD and other 
forms of inflammation51, 52.  
Other examples of T3SS effectors affecting the MAPK and NF-kb pathways include 
OspF and OspG derived from Shigella53, 54. OspF is a site specific phosphothreonine lyase, 
which irreversibly removes phosphate groups from p38 in the MAPK pathway54 inhibiting 
phosphorylation and signaling. OspF has also been shown to inhibit histone H3 phosphorylation, 
impairing the access of NF-kb with its promoter region and thus inhibiting inflammatory genes 
and cytokines55. OspG blocks ubiquitinylation of Iκβα, preventing NF-kb signaling56. VopA 
from Vibrio parahaemolyticus is an acetyltransferase that inhibits the MAPK pathways by 
acetylating a conserved lysine found on the catalytic loop of all MKKs thereby preventing 
binding of ATP57. This makes VopA potent inhibitor of cytokine production even though VopA 
has no effect on the NF-kb pathway58. AopA from Aeromonas salmonicida is also reported to 
attenuate host immune response by inhibiting immune deficiency (IMD) and Toll NF-kb 
pathways in Drosophilia. AopA prevents the nuclear translocation of p50/p65 Rel proteins59 in 
the NF-kb pathway, however, has no effect on the MAPK pathway. Plant pathogens such as 
Ralstonia solanacearum, Pseudomonas syringae, and Xanthomonas campestris have also been 




Another acetyltransferase virulence factor, YopJ derived from Yersinia, is an ortholog of 
AvrA61. It is involved in bacterial infection by acetylating serine and threonine residues of all 
MAP kinase kinases (MKKs)62 and on the activation loop of IKKβ63, thereby downregulating 
MAPK and NF-κB signaling, respectively. This leads to inhibition of host immune response and 
induces apoptosis61. Interestingly YopJ activity is shown to be cell type specific. YopJ is able to 
induce apoptosis in macrophages and dendritic cells64 but not in neutrophils and endothelial 
cells65. AvrA has also been shown to be differentially expressed depending on the organ location 
of infection66. This seems to suggest that these bacterial effectors rely on cell specific cofactors 
and triggers from their eukaryotic host for activation. Inositol hexakisphosphate (IP6) and/or 
coenzyme A (CoA) has been shown to be one of these triggers required for allosteric regulation 
of all acetyltransferases67, 68, 69. AvrA, YopJ, and its other orthologs are stored in a non-active 
conformation inside the bacterial pathogen until it is secreted by T3SS and binds IP6 and/or CoA 
to induce an allosteric conformation change to an active state inside the host cell. Furthermore, 
AvrA is known to be phosphorylated48 at evolutionarily conserved residues dependent on the 
host ERK pathway that is regulated by other bacterial effectors48. This implies that the activity of 
AvrA may be controlled by other effectors in its own feedback loop through the regulation of a 
host signaling pathway44.  
To date, serine/threonine acetyltransferases have not been reported in eukaryotes67. 
Structural analysis of acetyltransferases shows the complex mechanism of enzymatic activity 
based on allosteric regulation controlled by eukaryotic hosts. This could inspire further research 
toward understanding of acetylation as a prevalent post-translational modification and allow us 
to design drugs that can specifically target these bacterial virulence agents without affecting host 




diseases through a novel mechanism developed over millennia of co-evolution between pathogen 
and host. Chronic inflammation in inflammatory bowel is currently treated with nonspecific, 
systemic small molecules can produce unwanted side effects. The ability to reduce inflammatory 
signaling without apoptosis is a highly desirable feature that can be achieved with bacterial 
effectors. However, a major challenge in realizing the therapeutic potential of AvrA, or any 
exogenous protein effector, is the ability to deliver it locally through the harsh environment of 
the gastrointestinal tract, and into the cytosol of resident epithelial and immune cells without 
compromising the biological activity of the protein. Salmonella meets this challenge through use 
of T3SS. However, in Salmonella infection AvrA is co-delivered along with other virulence 
proteins,48, 70 which can have negative effects, such as promotion of colonic tumorigenesis.71, 72 
Therefore, an alternative delivery approach is necessary to deliver only AvrA in the absence of 
Salmonella and safely access its anti-inflammatory functions. The trigger responsive T3SS in 
Salmonella and other gram-negative bacteria span three cellular membranes, the bacterial inner 
and outer membranes and the eukaryotic host membrane. This enables pathogenic bacteria to 
package and protect protein effectors from degradation, gain access to the cytosol and other 
intracellular compartments, and release these proteins with spatiotemporal control38. Without this 
specialized and evolved delivery system, intracellular protein delivery remains highly elusive 
despite the great potential of largely untapped targets73.  
 
 
1.3 Approaches to Intracellular Protein Delivery 
 
It is estimated that only about ~5-10% of the druggable genome is being targeted by 




be targeted using protein drugs. Protein drugs are advantageous compared to small molecules 
drugs76, 77 because they offer higher specificity, greater activity, and less toxicity conferred by 
protein’s large size and conformation. There is a shift in pharmaceutical strategies favoring more 
protein-based drugs and this is seen in the growing number of proteins in the top selling 
pharmaceutical drug list along with an increase in protein biologicals gaining FDA approval78, 79. 
However, most of these proteins bind extracellular cytokines such as TNF-α or bind cell surface 
receptors for insulin, TNF-α, CD20, VEGF, PD-L1, or HER279. There exists a trove of potential 
protein targets inside the cell as well.  Intracellular proteins play a fundamental role in 
maintaining all cellular activities. Missing, malfunctioning, or poorly expressed proteins in cells 
is the cause of most genetic diseases. Delivery of functional proteins can be an unambiguous 
method of treating these genetic disorders80 and they can also be used stimulate or inhibit cells 
by manipulate signaling pathways, such as with effector proteins described in Section 1.2. 
Small molecules drugs face lower barriers to intracellular delivery because they are 
generally capable of diffusing across the membrane and into the cytosol of cells. The structural 
complexity of proteins presents several challenges to intracellular delivery. Proteins have limited 
transport to cells because they are susceptible to denaturation from changes in their local 
environment, enzymatic degradation from proteases, rapid clearance from the body resulting in 
short circulation half-life, and poor membrane permeability. Cells can engulf proteins in the 
extracellular environment via energy-dependent transport called endocytosis. Once proteins are 
endocytosed, they are enclosed within vesicles/endosomes destined for lysosomal degradation or 
to be recycle and exocytosed73 leading to low delivery efficiency and bioavailability. Great 




internalization, however, endosomal escape remains a formidable barrier80 to achieve the 
therapeutic potential of proteins.  
Approaches to improve the intracellular delivery of proteins include mechanical 
membrane disruption81, 82, covalent protein fusion modifications83, and NP-based carrier 
delivery77, 80, 84. These methods to improve intracellular delivery must be appropriately designed 
and formulated to protect the protein cargo from degradation, denaturation, aggregation, and 
minimize immunogenic side effects77 before reaching its therapeutic site. These methods should 
also facilitate targeting to diseased cells and if endocytosed, methods should enhance the 
endosomal escape of the protein.  
 
1.3.1 Mechanical membrane disruption 
 
The most straightforward method of delivering proteins intracellularly is by mechanical 
disruption. Direct insertion, such as with microneedles and nanoneedles, uses solid contact to 
concentrate pressure to a limited region of the plasma membrane causing a discontinuity in the 
membrane barrier. Afterwards, a controlled amount of protein can be injected directly into the 
cytoplasm and even guided to specific organelles such as the nucleus85. Despite its efficient 
method of intracellular delivery, direct insertion suffers from having low throughput capacity 
and requiring the use of specialized tools to inject into single cells. This method is generally 
limited to in vitro applications as single-cell localization is not achieved in in vivo applications82. 
Advances in microfluidics and jet injection, which employs a high-velocity ultrafine stream of 
proteins in solution instead of a needle, have automated this system of injections and has greatly 
increased throughput86. Another interesting example uses microfluidic constriction or cell 




biomacromolecules with low cytotoxicity81, 87. Current limitations are the inability to 
accommodate a heterogeneous population of cell sizes as the size of pores formed through 
squeezing are dependent on the cellular volume. 
Electroporation has been the leading technique of membrane disruption capable of 
delivery to millions of cells88 and its adoption in research has produced commercially available 
systems82. A typical electroporation setup includes a suspension of cells in between parallel 
plates where brief electric pulses are used to form a distribution of transient pores in the cell 
membrane89. This conventional setup produces a heterogeneous population of short lasting large 
pores and longer lasting small pores that allow the diffusion of materials into the cell. Nucleic 
acid delivery by conventional electroporation is more efficient than for other biomacromolecules. 
Electroporation partially embeds nucleic acids in the pores due to their dense negative charge 
resulting in subsequent internalization through receptor mediated pathways instead of direct 
delivery89. For other biomacromolecules, the higher voltages are required to stabilize larger pores 
results in higher propensity for aggregation and higher cytotoxicity81. The inconsistent level of 
membrane disruption between cells can also result in either insufficient delivery or excessive cell 
damage90. Efforts are being made to improve this system using more directed nanochannel 
electroporation combined with microfluidics. This combination of techniques concentrates an 
electric field over a very small area of the cell membrane allowing electrophoretically driven 
flow into the cell91. Similar to the direct injection method, electroporation is limited to mainly in 
vitro and ex vivo applications as it is difficult control in vivo and increases the possibility of 
influx from other proteins into the cell creating side effects92. 
Other methods of mechanical membrane disruption include sonoporation or using 




over other physical delivery methods in vivo due to the comfort and familiarity in clinical 
settings82. Thermal deviations can promote membrane defects from intense thermal fluctuation 
causing dissociation of lipids. Live cells have shown to leak at 42oC, and above 55oC small 
molecules (<1 kDa) rapidly diffuse in and out of cells93. At sub-physiological temperatures, ice 
crystals can form pores that heal when thawed. Cells subjected to rapid thermal phase transition 
between 0oC and 40oC can also promote intracellular delivery. Thermal methods seem to be 
confined to small molecule delivery and there are few reports on larger biomacromolecule 
delivery88. Optoporation with lasers produces membrane defects through a combination of 
mechanical, thermal, and chemical effects from ROS production94. Concerns about the 
destructive power of laser radiation along with need to precisely control the alignment and 
position of the laser beam to minimize off target ablations makes this low throughput method 
limited to those who can operate this expensive and sophisticated equipment82. A few 
biochemical methods are also used to cause membrane disruption. Detergents such as digitonin 
and saponin can disrupt cholesterol rich membranes or pore-forming toxins such as streptolysin 
O95 can generate large pores to allow delivery of proteins. The exact mechanism of pore-forming 
toxins is guided by an unknown mechanism and pore sizes when detergents are used are highly 
inconsistent96.  
These membrane disruption techniques have strengths as universal intracellular delivery 
systems, however, they are limited to in vitro and ex vivo applications since direct physical 
access to targeted cells is necessary. Transitioning these methods into the clinic requires 
controlled single cell delivery and currently, electroporation and sonoporation have only been 
somewhat effective at targeting sections of tissues. It is difficult to control cavitation evenly 




higher risk of inflammation from metal ion deposition originating from the electrodes. 
Electroporation also requires skilled technicians to properly place the electrodes to prevent injury 
from off target electric generation97. Other general common weaknesses such as high cell-to-cell 
membrane damage variability, restriction to either adherent or suspended cells, poor throughput 
and scalability, and not fully understanding cellular membrane recovery has shifted research to 
using microfluidics as a means of overcoming these challenges88. As the ability to scale up these 
methods improve, further work must be done to transition these techniques in vivo with minimal 
side effects.  
 
1.3.2 Covalent protein fusion modification 
Intracellular proteins therapeutic face challenges that elude small molecule drugs. The 
cell membrane is naturally impermeable to complexes larger than 1 kDa. The negatively charged 
cell membrane also contributes to repelling the majority of slightly negatively charged proteins 
as well. Unmodified proteins must enter cells through a mechanical disruption like the methods 
described above in section 1.3.1, or they must enter through bulk intact processes such as 
macropinocytosis98. Proteins must also maintain proper conformation and avoid proteolysis and 
clearance while reaching in vivo targets. These challenges have motivated research to covalently 
fuse moieties onto protein therapeutics that can help facilitate entry into the cell across the 
plasma membrane or extend its half-life in vivo. The strategy of covalently fusing moieties to 
therapeutic proteins is not limited to targeting peptides, but can also include full length proteins 
and polymers. Covalent modification has been an effective method of overcoming the challenges 




Viral pathogens have long been the inspiration for many drug delivery methods. Their 
effectiveness in vivo to deliver nucleic information has guided research in the field to study viral 
mechanisms and components with close scrutiny. One important discovery from research on the 
HIV virus was the ability of trans-activator of transcription (Tat) protein, to induce fusion with 
target membranes. Tat is a viral regulatory protein that binds RNA to activate transcription. A 
domain on Tat is responsible for its nuclear membrane localizing capabilities and when solely 
expressed, this cell penetrating peptide (CPP) retains its ability to cross the plasma membrane99. 
Since then, other naturally isolated CPPs have been reported, many other variants artificially 
created and mutated to increase bioavailability. CPPs vary in length, but are generally around 10-
30 amino acids depending on their mechanism of action. When a CPP is fused to an intracellular 
protein therapeutic, it greatly enhances the cytosolic delivery of a molecule many orders of 
magnitude larger than itself100. 1700 unique CPPs  have been cataloged101 that include 
experimental conditions such as the cell type and cargo. The ability of some regulatory proteins 
to localize in organelles has also been studied and the motifs responsible for localization have 
overlap with CPPs. CPPs can be engineered to provide subcellular localization along with 
enhanced delivery through the plasma membrane83. It should be noted that the efficiency of this 
plasma membrane penetration is debatable as it appears that once CPPs are conjugated to 
proteins, they are often concentrated within endosomes and unable to access the cytosol102, 103. 
The utility of CPPs is an area of active research and CPP conjugated drugs are being developed 
in clinical trials104.  
The first discovered and most studied PTDs are the Tat peptide and penetratin, a CPP 
from homeotic protein antennapedia in drosophila. They are both highly cationic peptides that 




other two classes of CPPs are either amphiphilic or hydrophobic in nature105, 106. Cationic CPPs 
rely mainly on positively charged arginines and lysines to form electrostatic interactions with 
anionic membrane lipids and components to facilitate crossing of the membrane. These cationic 
tails are typically covalently attached to the ends of protein cargo. Poly-arginine, poly-lysine, and 
poly-histidine CPPs were engineered to decode the mechanistic differences between the 
positively charged amino acids. It was found that arginine performed better than lysine and 
minimum of 8 arginine residues were required for internalization. Increasing the number of 
arginines led to higher levels of uptake, however, increased cytotoxicity as well107. It has also 
been reported that poly-arginines are quite efficient at lysosomal targeting as well105. Poly-
histidines have a disputed proton-sponge effect108 when 4 or 5 residues are present109. The 
supposed endosomolytic ability originates from histidine’s amine group that has a pKa of 6.2 and 
becomes pronotated at lysosomal pH, turning into a more cationic species. Nuclear localization 
sequences (NLSs) have some sequence overlap with cationic CPPs106. Lysine, arginine, and 
proline based NLSs were all found to localize in the nucleus by transporting across the nuclear 
pore complex. NLSs are shorter peptides that unable to penetrate other membranes making them 
poor CPPs alone.  
Another example that uses cationic charge to facilitate intracellular delivery is 
supercharged proteins110, 111. A green fluorescent protein (GFP) variant was first engineered to 
have very high net positive charge (+36 net theoretical charge to molecular weight ratio) and 
when conjugated to other proteins, this supercharged GFP variant was able to penetrate and 
deliver directly into mammalian cells. Since, other naturally occurring supercharged proteins 





Amphiphilic CPPs have both hydrophilic and hydrophobic regions that contribute to cell 
penetration. They are typically longer in length, around 20 amino acids, compared with other 
CPPs. The hydrophilic region can be cationic in nature to help promote electrostatic interactions 
with the negatively charged cell membrane, which allows the hydrophobic region of the CPP to 
embed itself into the membrane, facilitating penetration. Amphiphilic CPPs do not have to be 
cationic, and positively charged residues that have been mutated to anionic or neutral have been 
shown to be cell-penetrating as long as these residues remain polar. This suggests that 
amphiphilicity and mainly hydrophobicity is necessary for membrane translocation105, 106. Poly-
prolines can also exhibit penetrating capabilities such as the sweet arrow peptide (SAP)112. These 
alternating regions of hydrophilic and hydrophobic regions on amphiphilic CPPs can also 
assemble into secondary structures such as a-helices and b-sheets that are responsible for cell 
penetrating capabilities.  
Hydrophobic CPPs are emerging peptides. Hydrophobic CPPs have low net charge 
containing non-polar residues or hydrophobic motifs that confer membrane penetration. For 
example tryptophan residues improves hydrophobic interactions with the cell membrane because 
of their propensity to be buried within the cell membrane109. For the most part, the penetrating 
abilities of hydrophobic CPPs are also resistant to sequence scrambling, in contrast to most 
cationic and amphiphilic peptides. It has been reported that some of these hydrophobic CPPs can 
directly cross the cell membrane to avoid endosomal entrapment113.  
Combinatory CPPs with intracellular organelle targeting motifs have been gaining 
traction. Harnessing the penetrating abilities of CPPs coupled with the ability to localize protein 
therapeutics to organelles makes an extremely site-specific drug. CPPs on their own cannot 




their ability to target and penetrate organelle membranes. The NLS from the tumor antigen of 
simian virus 40 is one of the most studied, particularly in the field of gene therapy115. 
Commonalities between other known NLSs such as importin-a has shown that a strong positive 
charge mediated by basic amino acids located at the termini of proteins confers the ability to 
transport across the nuclear pore complex and achieve nuclear accumulation105. Lysosomal 
sorting peptides are 4-5 amino acids that are tyrosine based containing the patterns YXXØ or 
NPXY (Y – tyrosine, X – any amino acid, Ø – bulky hydrophobic side chain, N – asparagine, P – 
proline)116. Similarly, when used in conjunction with the tat peptide, they are able to localize 
cargo into lysosomal or lysosomal-like structures117. Szeto and Schiller (SS) have reported 
peptides capable of targeting mitochondria118 to reduce intracellular ROS activity. SS peptides 
are typically 5 amino acids and the common motif relies on alternating aromatic resides with 
basic/cationic amino acids. Modified tyrosines in the SS peptides with anti-oxidative abilities 
gives these peptides their intracellular mitochondrial therapeutic abilities. The golgi and 
endoplasmic reticulum are secretory pathways responsible for packaging and directing 
intracellular components to subcellular compartments including the plasma membrane. It also is 
responsible for carrying on posttranslational modifications on proteins making it a highly 
attractive avenue for targeting. The 4-peptide sequence KDEL added to the C-terminal used in 
conjunction with a N-terminal tat peptide is able to guide and retain cargo in the ER119. Recently, 
the antimicrobial peptide oncocin has been reported to target bacterial ribosomes120. Other 
proline-rich peptides from this oncocin family have also been shown to inhibit the ability of 
ribosomes to translate RNA. This expanding field of peptides capable of targeting intracellular 
organelles offers great potential to maximize the therapeutic potential of intracellular proteins by 




capabilities based on a similar cationic peptide sequence intrinsic to the zinc-finger structure121. 
When proteins are fused to the zinc-finger domain, it facilitates cytosolic delivery through 
micropinocytosis. 
 Albumin conjugation is another method of targeted intracellular delivery122. Albumin is a 
naturally occurring transporter protein that can engage cellular receptors to initiate 
internalization. Further engineering and biasing interactions toward glycoprotein receptors 
(Gp18, Gp30, and Gp60) can improve the intracellular delivery capabilities of albumin123. 
Albumin can be recycled by interactions with neonatal Fc receptor leading to longer half-life in 
vivo and allowing more opportunities for accumulation at target locations. Protein drugs smaller 
than 70 kDa are cleared from systemic circulation by renal filtration. Conjugation of these 
proteins with hydrophilic polymers such as PEG can reduce clearance by increasing their 
apparent molecular weight and/or hydrodynamic radius. PEG conjugation can achieve similar 
results of long lasting in vivo half-life by preventing clearance124. Albumin and PEG 
conjugations are nontoxic and have advanced into the market, indicating their widespread use 
and generally acceptability. Though these techniques are capable to extending half-life in vivo, 
their conjugation leads to alterations in physiochemical properties that can impart conformation 
changes affecting binding and activity125.  
 
 
1.3.3 Nanoparticle carrier delivery 
Although CPPs have been widely explored, their unclear exact mechanism of action, 
concerns about toxicity, and alterations in activity once actually conjugated to a therapeutic 
hinder their clinical applications77. NPs are another approach to intracellular delivery and though 




conjunctions with NPs further enhance their activity. NPs are inspired from viral pathogens. 
Viruses are highly efficient NP drug delivery vehicles and they are heavily studied both because 
of their harm to humans and potential to be repurposed for therapeutic delivery. Scientists and 
engineers have taken a reductionist approach to studying the virus and have refashioned many 
viral components. Viruses have been depleted of their native genes to prevent replication and 
pathogenicity and loaded with desired cargo, primarily nucleic acids. Viral vectors have been 
tested in clinical trials, however, challenges such as immune response, safety and complexity of 
viral preparations have hindered their ability to gain FDA approval for direct administration126. 
 Motivated by these limitations, a vast number of non-viral vectors have been developed88. 
These non-viral vectors generally try and accomplish similar goals as their viral counterparts 
such as loading and protecting cargo from degradation, target specific areas to maximize 
therapeutic benefit, and deliver cargo into the cytosol of cells to affect intracellular targets. These 
non-viral carriers original were engineered for nucleic acid transfection, however, they are being 
now being designed to deliver other biomacromolecules and proteins as well76. The deliver 
challenges are similar between nucleic acids and intracellular proteins. They are both too large to 
cross the cell membrane, they must escape endosomes to reach their therapeutic site, they must 
protect against nucleases and proteases, and they must accumulate in desired locations. Non-viral 
vectors can be made from inorganic nanomaterials, lipids, polymers, and proteins. Engineering 
these materials to be nanoscale makes them similarly sized or on the same order of magnitude as 
native viral pathogens possibly affecting how cells interacts with these materials. These materials 
have an enormous range in physiochemical properties such as charge, size, hydrophobicity, 
mechanical properties, composition, and function groups that can affect their ability to load, 




cellular uptake, endosomal escape, and target specificity80. One major problem with 
implementing these NP carriers is the inability to escape endosomes, leading NPs to lysosomal 
degradation or endosome recycling and exocytosis. It has been reported that only about 1% of 
lipid-based NPs actually make it to the cytosol based on studies delivering siRNA127, 128. This 
low efficiency could possibly be unique to siRNA therapeutic, however, it is much more likely to 
be generally applicable to all intracellular NP delivery vehicles. This means that there is a large 
potential for improvement. 
 
1.3.3.1 Inorganic 
 Inorganic NPs made from carbon nanotubes, quantum dots, magnetic materials gold, and 
silica have been used for the intracellular delivery of proteins and generally have excellent 
stability over a broad range of temperatures and pH values129, 130. Single-wall carbon nanotubes 
modified for water solubility and biocompatibility have been used to study delivery of proteins 
intracellularly. Proteins adsorbed onto the surface of the carbon nanotube enter the cell via 
energy-dependent endocytic processes131 and capable of intracellular delivery132. Some have 
reported that single wall carbon nanotubes are capable of membrane insertion and diffusion 
directly into the cytosol, though this mechanism of entry has been associated with thrombus 
formation as well80. Quantum dots have been widely utilized as fluorescent probes due to its 
narrow and tunable emission spectra. Intracellular protein delivery has been achieved with 
quantum dots only when used in combination with a CPPs and NLS133. Magnetically-mediated 
delivery approaches can increase the local concentration of target cargo and minimize non-
specific interactions. Magnetic NPs also possess an inherent diagnostic tool for magnetic 




theranostic nanoplatforms, though there have been few reports of using magnetic NPs to deliver 
proteins77. One report shows that magnetic NPs made from iron oxide hydrophobically and 
electrostatically bind proteins and enter endothelial cells134.  
Gold NPs have been extensively used in biomedical applications for its biocompatibility, 
with tunable surfaces via thiol group modifications, and unique spectroscopic properties135. 
Using the high surface area of gold NP, a combinatory lipid-HKRK (histidine – lysine – arginine 
– lysine) moiety was conjugated to its surface and used to delivery proteins to the cytosol of the 
cell with high efficiency136. These gold NPs formed complexes with protein to make protein-gold 
NPs and gold NPs can also stabilize nanoemulsions of oil. Using a mixture of protein-gold NPs 
and gold NPs to coat and stabilize an oil droplet, the oil droplets can then be used for the 
cytosolic delivery of therapeutic proteins.137, 138, 139.  
Proteins can be loaded through conjugation or adsorption onto the surface of gold, iron, 
carbon nanotubes, or quantum dot NPs. However, conjugation or adsorption directly exposes the 
protein therapeutic to serum and cells once they are administered in vivo, which could lead to 
proteolytic activity and cytotoxicity depending on the properties of protein therapeutic itself. 
Mesoporous silica NPs have been extensively studied because they are inert, non-immunogenic, 
and possess large internal surface area and pore volume allowing for high encapsulation140. 
These particles are able to protect protein therapeutics from proteases and denaturants because 
they are able to encapsulate proteins within their protective shell. This NP delivery system still 







Lipids are fatty acids with a hydrophilic head. This amphiphilic molecule can self-
assemble into NPs possessing bilayers, called liposomes, or single monolayers, called micelles. 
This allows various hydrophilic and hydrophobic compounds to be encapsulated141. Lipid NP 
sizes can be controlled based on the lipid formulation and they are able to inhibit access of 
proteases thereby maintaining protein activity. Cationic lipids have commonly been used to 
deliver nucleic acids due to strong electrostatic interactions. Modifying proteins to become more 
negatively charged, such as conjugating cis-aconitic anhydride, can increase the intracellular 
delivery capabilities when using cationic lipids80. These cationic liposomes can adhere to plasma 
membranes and enter the cell via endocytosis or by fusing with the cell membrane allowing for 
release of cargo directly into the cytosol of the cell142. Due to many possible formulations, lipid-
based NPs are capable of delivering almost any drug independent of its solubility. This stability 
however comes at a cost, the release profiles of these encapsulated proteins are not easily 
controllable and rely on lipid destabilization to release protein cargo143. Integration of cleavable 
disulfide bonds into the lipid can facilitate break up of liposomes once they reach intracellular 
reducing environments, facilitating release and delivery. Another advantage of lipid-based 
protein delivery systems is the ability to be lyophilized and administrated upon reconstitution. 
However, there are issues with immune response once their lipid-based delivery systems are 
administrated into the body. Serum proteins that mark materials for macrophage clearance, a 
process known as opsonization, adsorb onto the particles limiting their effect once implemented 
in humans144.  
Recently, exosomes have been gaining interest as possible drug delivery vehicles because 




derived from intermediate endocytic compartments known as multivesicular bodies that fuse 
with the plasma membrane leading to their liberation from the cell. Exosomes exist naturally as 
NPs and function as intercellular communicative tools between cells making them excellent 
candidates for drug delivery. This also makes them less immunogenic and less cytotoxic 
compared with cationic lipid-based NPs145. A current hurdle is that there is no distinct method of 
isolating exosomes with high purity, making scaling of this technology difficult. 
 
1.3.3.3 Polymeric 
Polymers are macromolecules that can be designed to be biocompatible and encapsulate 
and control release of therapeutic protein. The properties and morphology of polymeric NPs can 
be tuned by changing the molecular weight and composition of the repeating units used in the 
polymer backbone. Furthermore, polymeric NPs can be tuned to be stimulus responsive, 
meaning that the NPs can change their characteristics dependent on the environment around 
them. Environmental triggers can be temperature, pH, light, humidity, electric fields, magnetic 
fields, pressure, certain chemicals, such as glucose, or enzymatic, dependent on specific cell 
types or microorganisms146. Polymers can be engineered with multivalent binding domain to 
allow strong binding to proteins ensuring high capsulation, however, without specific binding 
domains, protein encapsulation in polymeric NPs is generally low77. Another common issue with 
using polymeric NPs for the delivery of proteins is the organic solvents essential for preparing 
protein-containing polymeric NPs125. The solvents can denature proteins thereby reducing their 
biological activity.  
Using a network of crosslinked hydrophilic polymers can produce hydrogels capable of 




Preparation of hydrogels is mild compared with other polymeric delivery systems as they do not 
rely on organic solvents. Hydrogels need to be crosslinked physically or chemically to prevent 
their dissolution. Their high water content makes hydrogels generally biocompatible and soft in 
nature allowing them to mimic natural extracellular matrices and prevent cell adherence144. They 
are able to load proteins physically with high capacity and protect protein cargo from enzymatic 
degradation, however, this is limited to proteins that are larger than the pore mesh sizes within 
the hydrogel147. Once encapsulated within the hydrogel network proteins have limited mobility 
or are immobilized, which is favorable for maintaining their 3D conformation. Nanogels have 
been engineered to deliver protein intracellularly relying on a pH sensitive or reducible linker to 
achieve release of encapsulated proteins147. These hydrogels can also be designed with stimulus 
responsivity allowing for hydrogel dissolution and rapid release of encapsulated therapeutics. 
Without hydrogel dissolution, encapsulated proteins must rely on diffusion and swelling of the 
hydrogel for release, which could be useful for sustained release applications. The tradeoff of 
favorable protein encapsulation is that hydrogels tend to have inherent low mechanical strength 
than hydrophobic polymers. In general, the release profiles of hydrogels are much shorter than 
that achieved by hydrophobic polymers, however, efforts are being made to increase the polymer 
concentration or alter crosslinking methods to impart a stronger hydrogel144. 
Another interesting extension of using polymers is using amphiphilic copolymers to form  
supramolecular assemblies resembling biological membranes148. In a similar fashion to 
amphiphilic lipids, amphiphilic copolymers can self-assemble into vesicles or polymersomes, 
allowing encapsulation of protein cargo for drug delivery purposes149. Similarly, these 
polymersomes can be designed to be stimulus responsive, providing site specific delivery of 




polymersome size, shape, stability, stimulus responsiveness, membrane thickness, fluidity and 
permeability148. Incorporation of several different copolymers can impart multifunctionality to 
polymersomes allowing construction of theranostic systems or enabling multi-targeting 
capabilities. However, how these artificial polymersomes interact with cell membranes will still 
need to be elucidated before they can be clinically implemented. 
 
1.3.3.4 Protein-based 
Proteins are natural macromolecules that contain unique functionality making them 
suitable materials for drug delivery purposes. They are biocompatible as the byproducts of 
protein degradation are amino acids which are well tolerated in vivo. Certain amino acids contain 
reactive functional groups suitable for crosslinking or conjugation. NPs can be made from 
proteins either by self-assembly or by covalent chemistry84. Virus-like particles (VLPs) are self-
assembled protein capsids that contain no viral enzyme protease, reverse transcriptase, and 
integrase making them safe and unable to replicate inside human cells. VLPs can made, but not 
limited to, from Gag protein derived from HIV. Fusion construct of Gag with therapeutic 
proteins allow VLPs to self-assemble and encapsulate the therapeutic protein inside the capsid 
allowing for intracellular delivery150. VLPs encapsulation efficiency is limited to the number of 
subunits that make up the capsid coat151. VLPs are efficiently internalized by cells, however, 
there is an inherent immunogenicity issue when using these viral proteins. Therefore their 
applications might be limited toward vaccination where generating a host immune response to 
crucial for success152. Protein ligands can also be attached onto the surface of the VLP allowing 
for extracellular delivery or binding cell surface receptors and triggering a cellular response150.  
Ferritin and ferritin-like cages are another well-defined hollow protein complex that can 




from 24 identical subunits. Genetic fusion of therapeutic proteins and peptides to ferritin subunits 
do not alter cage assembly and have been used to delivery immunogenic materials for vaccine 
delivery153. Ferritin cages are less than 30 nm and their small size allows them to access many 
parts of the body by passive diffusion and be efficiently internalized by cells. However, they 
limited by their ability to encapsulate significant payloads and most proteins must be displayed 
on the outside of the cage. Though this many be advantageous when targeting extracellular 
components such as cell surface receptors, it may not be suitable for intracellular delivery due to 
issues with proteases that can access the therapeutic agents. The E2 protein derived from 
pyruvate dehydrogenase multienzyme complex can self-assemble into a 24-mer hollow structure 
with a cubic core or a 60-mer icosahedron with twelve 5-nm openings depending the source of 
the E2 protein154. These cages are extremely stable under extreme conditions and proteins can be 
attached to its interior or exterior for drug delivery with similar properties to ferritin cages151. 
Protein vaults are barrel shaped hollow structures found in most eukaryotic cells assembled from 
ribonucleoparticles155. These structures are approximate 41 x 41 x 72.5 nm3 constituted mostly of 
major vault protein which makes up more than 70% of the overall mass. These major vault 
proteins though strong bound to one another, are non-covalently associated and impart a dynamic 
structure to the vault characterized by transient opening and closing known as breathing. This 
breathing process is known to be pH dependent, which can be utilized to load and release protein 
cargo based on pH stimulus. Protein vaults are not well understood like other protein cages, 
however, their unique structure and function indicate that there is potential for them to be 
successfully protein delivery vehicles151. Protein cages and vaults present unique monodispersed 
hollow structures that can be utilized for therapeutic protein loading on its interior or exterior, the 




useful applications for delivery to the extracellular targets because genetic fusion of therapeutic 
proteins to these hollow structures can be achieved with spatiotemporal control.  
Fusion proteins made with silk, collagen, or elastin can form various structures dependent 
on the primary sequence of the self-assembly motif156. These fusion constructs differ from 
protein cages and vaults as they are dense structures that can minimize unused space in the 
ultimate intracellular delivery vehicle. The most widely used is the elastin-like polypeptide 
(ELP), a thermal-responsive peptide made from repeating units of VPGXG (V – valine, P – 
proline, G – glycine, X – any amino acid except proline). These peptides are soluble at low 
temperatures and aggregate when heated above their transition temperature. When fused to a 
therapeutic protein, the ELP retains its thermoresponsivity allowing NP formation and 
delivery157. Its thermal-responsive and concentration-dependent coacervation allows for 
controlling the assembly and disassembly NPs and tuning the release of therapeutic protein151. 
Another interesting example is the genetic fusion of a therapeutic protein to a repebody158. 
Repebodies are engineered scaffold proteins adapted from leucine-rich repeats motifs that are 
commonly found in variable lymphocyte receptors. Variable lymphocyte receptors are a part of 
the adaptive immune response in jawless vertebrates and have a characteristic horseshoe-shaped 
solenoid fold that are researched as alternatives binding scaffolds to immunogloubulin 
antibodies158. Repebodies can be engineered to bind specific proteins, such as EGFR, and when 
fused to a therapeutic agent such as apoptin, self-assembly into NPs occurs driven by the 
apoptin159. This NPs are monodispersed, have high targeting, and have shown facilitate its 
intracellular delivery. The insights from these self-assembly driven techniques has led to design 
of minimal sequences for self-assembly using peptides. When cationic peptides based on poly-




functional nanoparticles160. Amphipathic peptides can be mixed with therapeutic proteins to form 
non-covalent complexes capable of intracellular delivery136. These cationic and amphipathic 
peptides are smaller than other self-assembly motifs and therefore can increase the ratio of 
therapeutic protein to assembly protein needed for delivery151. Cationic peptides still require 
genetic modifications, however amphipathic peptides do not. There are still issues of cytotoxicity 
associated with these cationic and amphipathic peptides similar to the CPPs discussed in Chapter 
1.3.2 that limit their intracellular applications. 
Desolvation is commonly used method to form protein NPs161. It is based on the 
differential solubility of proteins in different solvents. Typically, an organic solvent such as 
acetone or ethanol is added in a controlled manner to an aqueous solution of soluble protein. The 
addition of this desolvating agent leads to precipitation of the soluble protein. A schematic of the 
process can be seen in Figure 1.1. The size of the is dependent on protein concentration, 
desolvant, the volume ratio of desolvant to protein solution, pH, and temperature162. Heat and 
emulsions can also be used to form protein NPs, however, these techniques are generally produce 
larger sizes of NPs compared with the desolvant techniques and there is lower preservation of 
protein structure and function. Protein NP preparation made by heat results in denatured proteins 
and preparations made with emulsions must also remove all the oil before therapeutic use84. 
Glutaraldehyde is typically used to crosslink the NPs made through desovlation and using 
cleavable linkers can help make the NP stimulus responsive. An example would be a disulfide 
bond crosslinker that is capable of being reduced by intracellular GSH to break up the protein 
NP163. Crosslinking requires functional groups that can be found on some reactive amino acids 
such as primary amines on N-terminus and lysines, carboxyls found on C-terminus, aspartic acid, 




scale up potential makes it an attractive technique for producing NPs, however, use of organic 
solvents can denature some proteins and desolvated protein NPs are not as monodispersed as 
self-assembled structures. Desolvated protein NPs do not require fusion to a self-assembly motif 
and can theoretically achieve a much higher encapsulation efficiency.  
Typically, protein NPs have been used to deliver small molecules164, however, a protein 
NP could be made entirely of therapeutic protein and would be an effective carrier and therapy 
combined into one. If desolvated NPs are made entirely of the therapeutic protein, this would 
maximize therapeutic loading efficiency, however, retention of protein function after exposure to 
organic solvent and covalent crosslinking is crucial. Making protein NPs completely of 
therapeutic protein is sometimes not feasible if the therapeutic protein solubility is too low and 
therefore a carrier protein must be co-desolvated. The addition of a carrier protein can help 
reduce the size of the final protein NP preparation by increasing the starting protein 
concentration, a known variable to influence size. The carrier protein can also be another 
therapeutic protein or multiple therapeutic proteins to create a multi-functional NP. This 





Figure 1.1 Schematic representation of protein NP desolvation. Estimate of number of proteins 
per NPs are based on the theoretical volume of a protein based on molecular weight and the 
volume of a 250 nm spherical NP. 
 
  
1.4 Intracellular Nanoparticle Delivery 
Whereas traditional small molecule drugs enter cells mainly through passive diffusion 
through the cell membrane or active transport via binding to a cell surface receptor, NPs are 
typically internalized by cells via endocytosis165. Endocytosis is a group of energy dependent 
processes by which extracellular entities are internalized within a membrane vesicle called an 
endosome. Depending on the NP size, surface charge, surface hydrophobicity, and the cell type it 
is interacting with, the endocytic mechanisms by which it enters the cells can be vastly 
different166. NPs internalized via endocytic processes are enclosed within endosomes coated with 
different kinds of cytosolic proteins that polymerize on the cytosolic side of the membrane. 
These initial protein coatings dictate the intracellular trafficking mechanism and influence the 




as endosomes containing NPs are usually destined for lysosomal degradation or recycled and 
exocytosed127, 128. Endosomal escape is most desired so NPs can access the cytosol where many 
druggable targets reside. Though some therapeutics have function in endo/lysosomes and 
therefore do not require endosomal escape. The lysosome can be the desired location for treating 
lysosomal storage diseases or for vaccine delivery. Other delivery applications include 
transcytosis to cross cell barriers and reach a target tissue underneath, such as transcytosis 
through the lungs or the blood-brain barrier165. Therefore, understanding the endocytic 





Endocytosis is the process by which extracellular materials gain entry inside the cells. It 
be generally divided into phagocytosis, which is the uptake of large particles, or pinocytosis, 
which is the uptake of fluids and solutes. Furthermore, pinocytosis can be divided into receptor-
mediated process such as clathrin-mediated or caveolae-mediated and nonspecific processes such 
as macropinocytosis, though now more forms of pinocytosis are being elucidated such as arf6-
dependent, flotillin-dependent, cdc42-dependent, and rhoA-dependent processes167. Phagocytosis 
is a special type of endocytic pathway that is predominantly used by phagocytes, such as 
macrophages, used to clear large objects ranging from 0.5 µm – 10 µm, such as bacteria. If 
smaller NPs are to target this pathway, they must first be opsonized by immunoglobulins, 
complement components, and other blood serum proteins. The best-studied receptors that initiate 
phagocytosis are Fc receptors168, but mannose/fructose and scavenger receptors are also used for 




Unlike phagocytosis, which is reserved for phagocytes, clathrin-mediated endocytosis is 
performed by all mammalian cells and is an important pathway for nutrient uptake and 
intracellular communication166. Clathrin-mediated endocytosis is best classified by the clathrin 
coated pits that form around vesicles that invaginate from the cell membrane. Receptor-mediated 
clathrin endocytosis is the most studied mechanism however, clathrin coated pits are also known 
to form stochastically by the clustering of clathrin around a random collision event at the plasma 
membrane170.  
Caveolae-mediated endocytosis is defined by caveolae proteins that coat vesicles. This 
type of endocytosis is used abundantly by endothelial cells associated in regions of the lipid 
membrane with high cholesterol and lipid content171. Microdomains on the cell membrane 
containing high lipid and cholesterol content are called lipid rafts172. These unique features are 
the target for certain pathogens that utilize caveolae-mediated endocytosis such as the SV40 
virus173. Caveolae-mediated processes are also involved with transcytosis and uptake kinetics are 
known to occur at much slower rates than clathrin-mediated endocytosis168. Caveolae pits are 
much smaller flask-shaped vesicles, no larger than 50-80 nm, and there is no study that 
unambiguously shows that caveolae vesicles can accommodate NPs larger than 100 nm174.  
Macropinocytosis is another common endocytic process used by nearly all cells except 
endothelial cells found in the brain166. It is defined by non-specific membrane ruffling creating 
large vesicles called macropinosomes ranging from 0.5 µm – 10 µm. They are similar to 
phagosomes, except they form around extracellular fluid instead of solid objects.  
There are certain “guidelines” that influence the internalization and uptake of NPs. NP 
size is known to be a determinant of uptake pathways as well as being crucial to many other in 




each of the endocytic pathways is used as an approximation of the size of NPs that it can 
accommodate. Typically the sizes are proposed to be 60 – 80 nm for caveolae processes, ~100 
nm for clathrin processes, and particles up to several microns can be internalized through 
micropinocytosis and phagocytosis. There are instances where NPs larger than the clathrin 
vesicle size have been shown to utilize that pathway168. In general, it appears that many of these 
endocytic pathways can accommodate smaller particles, meaning more access to the cell and 
faster internalization. 
Surface charge can promote internalization through interactions with the cellular 
membrane. The negative charge of the plasma membrane means that cationic NP have an 
electrostatic force driving association and increasing internalization rates. Anionic NPs 
experience repulsive forces from the cell membrane. However, they can be captured by cells 
through interactions with positive sites on membrane proteins175. Neutral NPs can interact with 
cells by hydrophobic interactions and hydrogen bonding176. Cationic NPs have been reported to 
enter cells mainly through clathrin mediated endocytosis, anionic NP through caveolae-mediated 
endocytosis, and neutral NPs via all routes with no preference166. However, additional reports 
showing that cationic and anionic NPs can utilize several or all these pathways highlights the 
complexity of cellular internalization of NPs. 
Hydrophobic NPs have a higher attraction to the cell membrane than hydrophilic NPs, 
leading to increased uptake kinetics. Poly-ethylene glycol (PEG) has long been used as a surface 
modification to increase the hydrophilicity of NPs, extending circulation times by preventing 
uptake and clearance. Hydrophobic NPs have been reported to be internalized by endothelial 
cells through caveolae-mediated endocytosis177. Since caveolae is predominantly localized on 




Of particular interest is the protein corona that opsonizes NPs once they enter biological 
media. Though some physiochemical properties of NPs are highlighted here as influencing the 
cellular endocytic processes, it is now known that “bare” NP surfaces are rarely “seen” by the 
cell. Rather, serum proteins compete and bind to the surface of NPs and this layer, called the 
protein corona, defines the biological identity of the NP178. The total protein concentration in 
serum is around 60 – 80 mg/mL. When NPs enter the bloodstream, large quantities of serum 
proteins weakly bind to the surface and over time are replaced by higher affinity proteins 
following the Vroman effect179. The higher affinity proteins that bind to the NP surface do so 
irreversibly forming the inner “hard corona” where lower affinity proteins protein reversibly bind 
forming the outer “soft corona”. A new report shows that the corona morphology is not a dense 
shell around the NP, but rather a loose network of proteins180. This network of protein is 
ultimately what interacts with cells, allowing interactions of specific serum proteins with cell 
surface receptors to dictate internalization. 
Different NP physiochemical characteristics were discussed previously as influencing 
cellular internalization. It is more accurate to portray NP characteristics as influencing the corona 
that forms around the NP, which will ultimately interact with the cell surface and influence 
internalization. NP size affects the amount of protein in the corona with larger NPs having more 
total proteins and smaller NP having increased corona thickness with decreased conformational 
changes of the adsorbed proteins179. NP charge affects the conformation of the adsorbed corona, 
with cationic NPs denaturing proteins and anionic NPs maintaining protein conformation181. NP 
hydrophobicity can also increase the amount of proteins in the corona, increasing affinities of 
specific types of serum proteins, and causing more conformational changes179. Hydrophilic NPs 




clusterin182, 183. The environment in which corona adsorption occurs such as temperature, pH, 
shear stress, and exposure time can also affect corona composition166. Most studies on protein 
corona are performed on hard NPs such as gold or polystyrene. Protein NPs would theoretically 
have softer mechanical properties, behaving more like hydrogels. The corona on hydrogels 
altered based on stimulus responsive hydrophilic polymers allowing tuning of the corona 
composition on NPs184. The protein corona has not been studied on protein NPs and they may 
behave differently from other NPs since their surface is already comprised of proteins.  
 
1.4.2 Intracellular trafficking mechanisms 
Regardless of the pathways NP use to enter the cell, they are all enclosed within vesicles 
limiting access to the cytosol. This is a major roadblock to utilize NPs for delivery of 
intracellular protein therapeutics. The initial stage vesicles used to engulf NPs at the cell surface 
are well known and defined. Materials that enter the cell via phagocytosis are entrapped within 
phagosomes. Material inside phagosomes are destined for degradation and destruction by 
acidification and enzymolysis by fusion with early endosomes and eventually lysosomes185. 
Generally, NP delivery aims to avoid this pathway since the usual goal of delivery is to reach the 
cytosol before lysosomal destruction unless the target of delivery is the lysosomes themselves or 
if the NPs have a pH or enzymatic trigger.  
Clathrin-mediated endocytosis is defined by the cytosolic clathrin proteins that coat the 
vesicles during membrane bending. Once internalized in the cell, the clathrin lattice will 
eventually uncoat the vesicle allowing recycling of the clathrin units170. These uncoated vesicles 
will deliver and fuse their cargo to early or sorting endosomes that are slightly acidified (pH ~ 6). 




maturation, late endosomes will fuse with lysosomal vesicles with the harsh acidic and 
enzymatic environment that will degrade the contents of the vesicle.  
Caveolae-mediated endocytosis is typically associated with lysosomal avoidance and is 
the preferred route of many pathogens186. Once caveolae coated vesicles invaginate into the cell, 
they fuse with caveosomes or multivesicular bodies, which have neutral pH and lack the 
enzymes that are typically found in early endosomes187. Due to the mild vesicular environment 
found within caveosomes, targeting caveolae-mediated uptake has been sought as the preferred 
pathway for nanocarriers. However, it is now debated whether the caveosomes actually exist as 
their own entity or if they are actually early endosomes188. Multivesicular bodies can also 
become lysosomes facing the same fate as clathrin vesicles189. It appears that once these coated 
pits shed their coat proteins and enter the milieu of other vesicles that reside in the cell, it is hard 
to determine the ultimate fate of these vesicles. 
Macropinosomes are distinct from other endocytic pathways as they do not have any 
specific coating on them. The intracellular fate of macropinosomes seem to be dependent on the 
cell type, as macrophage macropinosomes fuse with lysosomes and epithelial macropinosomes 
are recycled and release their contents back into the extracellular space190. Though in most cases, 
macropinosomes fuses with multivesicular bodies and eventually acidify and shrink168. 
Macropinocytosis also seems to be an important mechanism for nutrient uptake in cancer cells, 
which tumor cells rely on to meet their unique metabolic needs191. This supports the notion that 
though macropinocytosis is highly conserved in many cells, each cell type utilizes this non-
specific endocytic pathway for different needs. 
Previously it seemed as though the endocytic uptake mechanism could dictate or 




case192. Crosstalk between the different pathways and new clathrin- and caveolae-independent 
endocytic pathways have introduced even greater levels of complexity of the trafficking 
mechanisms in a cell. The low cytosolic delivery efficiency common to many NP delivery 
vehicles has been a significant challenge. Several techniques have been developed that are 
reported to promote the endosomal escape of NPs. Methods such as proton-sponge effect, which 
utilizes the buffering capacity of unprotonated moieties, such as amines, to absorb protons during 
pH drops leading to an influx of water that eventually bursts the endosome. This mechanism is 
heavily debated108 though the effects of release and delivery are still observed. Amphiphilic and 
hydrophobic CPPs described in Chapter 1.3.2 have also been reported to associate with 
membrane leading to escape. Many of these techniques still suffer from low efficiency and 
cytotoxicity193. Most vesicles, once internalized, will follow a similar evolution of early 
endosome to late endosome to lysosome or recycled and exocytosed. Endosomal escape mainly 
focuses on the pH change as a trigger for moieties that can promote membrane disruption and 
release though some endosomes may be quickly recycled and never exposed to these triggers. 
Further studies are needed to elucidate these complex trafficking mechanisms to enable design of 
NPs with improved delivery efficiency and possibly allow for localization to subcellular targets. 
 
1.5 Oral Delivery 
 
NPs have been used for both localized intestinal delivery and systemic delivery although 
these appear to be two seemingly different goals194. Systemic delivery is most commonly achieve 
with injections as other routes (buccal, nasal, pulmonary, transdermal, oral) face difficult barriers 
amounting to extremely low bioavailability194. For IBD therapeutics, localized intestinal delivery 




delivery is the most pertinent and logical for treating inflammatory bowel disease as therapeutics 
must reach localize in inflamed regions of the intestine. The oral route is not sensitive to drug 
size and has a more favorable safety profile due to minimal systemic exposure and reduced 
immunogenicity, as well as having improved patient compliance195. 
Excluding oral vaccines, there are only six biomacromolecules that are Food and Drug 
Administration (FDA) approved for oral delivery in the nearly 100 years since the first attempts, 
speaking to the difficulty of oral administration195. The gastrointestinal tract is evolutionally 
optimized to break down proteinaceous materials. Acidic pH in the stomach denatures and 
unfolds protein allowing enzymes in the stomach to recognize and access more motifs for 
cleavage. After leaving the stomach, enzymes present in the small intestine and colon continually 
work to cleave proteins into small fragments allowing them to be absorbed as nutrients. The 
presence of mucus creates a physical barrier made up of constantly renewing negatively 
glycoproteins limiting access to the epithelial cells that reside underneath.  
Common methods to increase the oral bioavailability of protein therapeutics involve 
using protease inhibitors to prevent enzymatic degradation and permeation enhancers to facilitate 
transport across mucus and through the epithelium196, 197. These methods have traditionally been 
used for systemic delivery of soluble proteins and chronic use of these inhibitors and enhancers 
can lead to severe side effects198. Conjugating proteins with cell penetrating peptides or 
mucoadhesive polymers can increase targeting and minimize off-target effects. However, these 
methods still suffer from low penetration and bioavailability from natural mucus turnover198.  
NPs can be used to target inflamed tissue. Inflamed mucosa induced by IBD exhibits 
different properties than healthy mucosa. A consequence of inflammation is the disruption in the 




permeability is similar to the enhanced permeability and retention effect observed in tumors199. 
NPs preferentially localize in these areas of the intestine as a function of size. 100 nm particles 
localize better than 1 µm particles, which localize better than 10 µm particles200. Anionic NPs are 
also reported to localize better in inflamed tissue than cationic particles due to the increased 
presence of positively charged transferrin and proteins from eosinophils201. They also face less 
resistance diffusing through the mucos layer due to electrostatic repulsion. Cationic NPs show no 
preference toward inflamed tissue as they exhibit mucoadhesive properties due to electrostatic 
interactions with the negatively charged mucus layer. Regardless of charge, NPs possess passive 
targeting to inflamed mucosa with smaller NPs able to localize to a greater extent. Gastric 
passage remains an issue as the stomach as it is the first major obstacle protein therapeutics 
encounter. 
Therapeutic soluble proteins have been co-delivered with protease inhibitors to prevent 
enzymatic degradation and permeation enhancers to facilitate transport across the epithelium196, 
197. These methods have traditionally been used for systemic delivery of proteins, though chronic 
use of these inhibitors and enhancers can lead to severe side effects198. Conjugating proteins with 
cell penetrating peptides or mucoadhesive polymers can increase targeting and minimize off-
target effects. However, these methods still suffer from low penetration and bioavailability from 
natural mucus turnover198. To overcome these challenges, localized intestinal delivery of protein 
therapeutics has typically been accomplished by NPs or MPs made from biodegradable polymers 
and hydrogels194. NPs are able to passively target inflamed tissue202, enhance mucus penetration, 
and membrane permeation203. MPs can provide a larger depot for protein therapeutics that can be 
engineered to be stimulus responsive204. NPs and MPs can improve protein stability and be 




oral system (NiMOS)205, combines these two particulate systems in a unique approach for oral 
gene delivery206, 207. Gelatin NPs encapsulating plasmid DNA were then encapsulated in 
poly(epsilon-caprolactone) MPs and shown to transfect the small intestine and colon of rats. 
NiMOS has the advantages of both NP and MP delivery systems as NPs were capable of 
penetrating the mucosal barrier and MPs protected NPs from enzymatic degradation until they 
reached the absorbing epithelium. 
Alginate and chitosan are two natural polysaccharides generally regarded as safe (GRAS) 
by the FDA that have been used as NPs or MPs for oral delivery of insulin208, 209, 210, BSA211, 212, 
hemoglobin213,  probiotics214, 215, and cells216, 217. Alginate can form hydrogels under mild 
gelation conditions ideal for protein encapsulation218. A chitosan coat can be used in conjunction 
with alginate hydrogels to remedy the problems of drug leakage219. Alginate hydrogels shrink at 
gastric pH and the complementary electrostatic properties of anionic alginate and cationic 
chitosan allow interpolymeric associations strengthened by the protonation of chitosan amine 
groups at low pH. At intestinal pH, which ranges from pH 6 to pH 7.5 depending on location in 
healthy individuals but is lower in IBD patients220, alginate hydrogels swell and the charge of 
chitosan reverses to negative, allowing release of encapsulated cargo. Alginate/chitosan MPs can 
also protect against enzymatic degradation by providing steric hindrance and lowered collision 
opportunities. Mammals lack alginase221 and chitosanase (though have chitinase222) meaning that 
alginate and chitosan do not get digested in vivo, but rather rely on the ionic exchange between 
the crosslinked calcium ions with extrastitial monovalent sodium or potassium ions to break up 
the alginate core.  
In UC, a form of IBD that mainly localizes in the colon, colon-specific targeting is 




commonly used are methacrylic acid copolymers (EudragitÒ)223. Varying the composition of the 
side groups can manipulate the pH at which these polymers dissolve, most commonly in the 
range of pH 6 – 7 allowing them to bypass the stomach while protecting the active therapeutic. 
Some issues with this polymer coating include the organic solvents used to dissolve the polymer 
and the need for careful tuning of different copolymers to achieve desired pH sensitivity223. The 
potential for degradation by bile acids in the duodenum can cause undesirable and premature 
drug release202. Patients with UC generally have lower colon pH than healthy individuals 
resulting in the polymer coating never dissolving. Redox-responsive targeting systems rely on 
the abnormally high levels of reactive oxygen species (ROS) produced by activated phagocytes 
in inflamed intestinal tissue. Polymers have been developed that cleave in response to ROS 
thereby releasing therapeutic compounds224. Colon targeting ligands can also be used to increase 
therapeutic efficacy and reduce side effects. I-CAM is known to be upregulated in inflamed 
regions of the colon and antibodies can be used against these adhesion sites. Using antibodies as 
targeting ligands suffer the same obstacles as protein therapeutics and NPs using these targeting 
antibodies were shown to deposit in the stomach and upper GI tract225. Targeting macrophages 
via mannose receptors, macrophage galactose-type lectin, and F4/80 surface receptors to deliver 
siRNA have shown positive results as macrophages are the primary perpetuators of inflammation 
in IBD202.  
 
 
1.6 Motivations and Objectives 
 
Inflammatory bowel disease is a debilitating disease and there are significant side effects 
for current small molecule treatments. Protein drugs are highly specific and possess several 




components or cell surface receptors, there exists abundant intracellular components that can 
modulated as well. AvrA, a bacterial effector enzyme with intracellular activity, is introduced as 
a potential therapeutic for chronic inflammation with dual anti-inflammatory and anti-apoptotic 
effects. AvrA is an evolved enzyme possessing a mechanism of action not found in eukaryotes, 
making AvrA a unique therapeutic to combat disease. The barriers to cytosolic delivery of 
enzymes with intracellular activity are high and many of the methods used suffer from low 
encapsulation or reduce the activity of the therapeutic protein during fabrication. Protein NPs 
offer a means of cytosolic delivery. However, it is not understood how the properties of protein 
NPs affect their intracellular delivery and cytosolic localization. In particular, the properties are 
likely to affect the protein corona formed upon contact with physiological fluids, which in turn 
has a significant effect on cellular uptake and trafficking.  
Implementing therapeutic AvrA protein NPs for the treatment of inflammatory bowel 
disease requires delivery to inflamed regions of the intestine to maximize therapeutic benefit. 
Transrectally delivery is an effective method for AvrA NPs, however, this route is undesirable 
for patients and the limited area of therapeutic effect prevent its clinical use. Oral delivery of 
protein therapeutics is advantageous, but difficult, because the stomach functions to break down 
proteinaceous materials. Therefore, the gastric passage and intestinal release of protein NPs is 
crucial for the clinical implementation of AvrA NPs. 
 The objectives of this thesis are: (1) engineer protein NPs to enhance the intracellular 
delivery of functional AvrA, (2) maximize cytosolic delivery of AvrA by altering protein NP 





1.7 Thesis Overview 
The overall goal of this thesis is to develop therapeutic AvrA NPs for the treatment of 
inflammatory bowel disease. To accomplish the objectives stated in the previous section, Chapter 
2 details the synthesis and characterization of protein NPs as delivery vehicle for AvrA and 
evaluates their performance in vitro and in vivo. In Chapter 3, an oral delivery vehicle is 
engineered for the gastric protection and intestinal release of AvrA NPs. In Chapter 4, protein 
NPs with various physiochemical properties are developed to study the role of adsorbed corona 
and its contributions to cytosolic delivery. Finally, Chapter 5 summarizes the work in this thesis 

























CHAPTER 2 : AvrA Nanoparticles for Treatment of Inflammatory Bowel Disease 
 
2.1 Introduction 
IBD (CD and UC) are chronic relapsing autoimmune disorders of the intestinal tract that 
affect 1-2 of every thousand persons in developed countries and incidence is increasing.5, 6 In the 
intestine they manifest with acute and chronic inflammation, tissue injury, scarring and 
predisposition to adenocarcinoma, and may also have systemic effects. IBD is generally 
recognized to represent aberrant immune recognition of the normal commensal microbiota. 
Current therapy involves inflammatory suppression with local 5-aminosalicylates, systemic 
corticosteroids, cytotoxic immunosuppressants, or biologicals, such as anti-TNF monoclonal 
antibodies. While effective, these are fraught with the complications of systemic 
immunosuppression and other toxicities.10, 11 There is increasing interest in use of beneficial 
bacteria (probiotics) as a therapy, though to date only modest efficacy has been reported.226 
It is known that enteric bacterial pathogens have evolved mechanisms to suppress 
inflammatory and immunoregulatory pathways through active interference with regulators of the 
inflammatory response.35, 36 Enteric pathogens influence eukaryotic pathways by soluble effector 
proteins that are translocated into the cytoplasm of target cells via a T3SS and have evolved to 
usurp host cellular functions for the benefit of the invading organism.227 AvrA, from Salmonella, 
is one such protein. It is a member of a family of acetyltransferases that covalently modify and 
inactivate members of the MAPK superfamily, and thus have potent and diverse effects on a 
wide variety of eukaryotic growth, survival and immune pathways.42 We have shown that AvrA 
overexpressed in transfected cells,41 or in a Drosophila transgenic model,47 blocked activation of 
NF-κB, JNK MAPK, and transcriptional activation of a range of inflammatory effector genes. 




similar effects in a yeast model.48 Remarkably, in yeast, flies, human cells and murine intestinal 
epithelia, AvrA-mediated signaling blockade occurs without induction of the apoptotic cell death 
characteristically seen during inhibition of host stress signaling pathways,41, 42, 47, 48 thus making this activity an 
ideal therapeutic approach for IBD or other forms of inflammation. However, a major challenge 
in realizing the therapeutic potential of AvrA, or any exogenous protein effector, is the ability to 
deliver it locally through the harsh environment of the gastrointestinal tract, and into the resident 
epithelial and immune cells without compromising the biological activity of the protein. 
Salmonella meets this challenge through use of TTSS. However, in Salmonella infection AvrA is 
a SPI-1 TTSS effector protein that is co-delivered along with other virulence proteins,48, 70 which 
can have negative effects, such as promotion of colonic tumorigenesis.71, 72 Therefore, an 
alternative delivery approach is necessary to deliver only AvrA in the absence of Salmonella and 
safely access its anti-inflammatory functions. 
NPs have been investigated for a variety of intraluminal gut applications including 
vaccination,228 diabetes,229 and IBD224, 230, 231, 232, 233, 234, 235 that target different cell types for systemic or local 
delivery. Previous IBD studies have encapsulated small anti-inflammatory drugs or siRNA in 
biodegradable polymeric micro and NPs.232 The primary benefits seen were reduced systemic side 
effects and reduced dosage required for the same therapeutic response. Furthermore, higher 
particle deposition has been seen in animals with induced colitis as compared to healthy animals, 
perhaps a consequence of depleted mucus, presence of phagocytic cells, or epithelial barrier 
disruption observed in inflamed tissue.200, 232, 233, 236 In the case of protein drugs, however, polymeric 
delivery particles have limitations. Protein loading is extremely low or the particles are too large 
to be internalized by cells, and harsh fabrication or degradation conditions can damage the 




cross-linked protein NPs made from AvrA that can uncross-link in the reducing environment 
observed inside cells, while maintaining the bioactivity of the AvrA cargo (Figure 1.1). With 
these particles, we demonstrate the ability to suppress proinflammatory pathways in vitro and 
tissue inflammation in murine model colitis. This innovative approach has potential as a IBD 
therapeutic and establishes a drug discovery paradigm that exploits the evolution of bacterial 
immunoregulatory mechanisms and engineers a NP delivery strategy essential for clinical 
viability. 
 
2.2 Experimental Methods 
 
 
2.2.1 Recombinant production of AvrA, mAvrA, and eGFP 
eGFP gene was contained in a pPROTet plasmid (Clontech Laboratories) and was 
expressed constitutively in BL21 Escherichia coli with 34 µg/mL of chloramphenicol (VWR) in 
2XYT media. eGFP was purified on Ni-NTA agarose (Qiagen) following manufacturer’s native 
imidazole purification protocol.  
The AvrA/mAvrA gene was contained in a pGEX-4T-2 (GE Lifesciences) plasmid and 
expressed in AFIQ Escherichia coli with 34 µg/mL of chloramphenicol and 200 µg/mL of 
ampicillin (VWR) in 2XYT media. AvrA bacterial cultures were grown to o.d. 0.7 at 37oC and 
induced with 0.4 mM isopropyl b-D-thiogalactoside (IPTG) at 25oC for 4 hr. AvrA was purified 
first with glutathione sepharose 4B (GE Healthcare) following manufacturer’s protocol and then 
repurified on Ni-NTA agarose following manufacturer’s native imidazole purification protocol. 
Purified proteins were concentrated using 10k MWCO centrifugal ultrafiltration devices 




buffer (250 mM imidazole, 50 mM sodium phosphate monobasic, 300 mM sodium chloride, pH 
8) determined by Nanodrop 2000c (Thermo Fisher Scientific) using MW = 26.95kDa and e = 
61000 cm-1 M-1 for eGFP and MW = 59.84kDa and e = 60910 cm-1 M-1 for AvrA. 
 
2.2.2 Nanoparticle synthesis through desolvation 
Protein particles were prepared by the desolvation technique as previously described162. 
In brief, 600 µg of eGFP and ~25 µg of AvrA-GST or mAvrA-GST in 100 µl imidazole solution 
(250 mM imidazole, 300 mM NaCl, 50 mM NaH2PO4; pH 8) were placed in a glass vial. The 
protein solution was desolvated by continuous, drop-by-drop addition of 400 µl ethanol at a rate 
of 1 ml/min. After desolvation, particles were crosslinked with 2 mg/ml 
Dithiobis(sulfosuccinimidyl-propionate) (DTSSP; Pierce) at a ratio of crosslinker to lysines of 
1:2.2. After 2 h stirring, the cross-linking reaction was stopped by centrifugation at 1000 g for 1 
min and removal of supernatant. Particles were re-suspended in PBS and sonicated on ice for 1 s 
every 15 s at 30% amplitude, for a total of 5 minutes.  
 
 
2.2.3 Size, zeta-potential, gels, and western blot characterization of nanoparticles 
Particle size distribution was measured by dynamic light scattering using a Zetasizer 
Nano ZS90 (Malvern Instruments Ltd). All samples were measured at 25°C and a scattering 
angle of 90°. Average particle size was calculated as the arithmetic mean of the distribution of at 
least 3 batches of particles and the standard deviation was calculated as the variance between 
average diameters of the batches using the following settings: proteins setting for NP detection 








2.2.4 Confocal microscopy for qualitative assessment of nanoparticle uptake 
J774.A1 cells were purchased from American Type Culture Collection and cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% (v/v) fetal bovine 
serum (FBS). J774.A1 cells were seeded at a density of 104 cells per well in an 8-well chamber 
slide system (Nunc LabTek II, Thermo Scientific) with growth medium. After 14 hours, cells 
were incubated for 6 hours with fresh cell media containing 300 µg/ml soluble AvrA-GST and 
eGFP or AvrA-eGFP NPs. Cells were washed twice with ice cold PBS and fixed with 3.7% 
paraformaldehyde for 15 minutes at room temperature. Cells were permeabilized with 1% Triton 
X-100 in PBS for 15 minutes at room temperature and rinsed three times in PBS. Cells were 
incubated with 2 µM TO-PRO-3 (Molecular Probes) and 0.165 µM rhodamine phalloidin 
(Biotium) in blocking buffer for 20 min at room temperature. Cells were washed three times with 
PBS and mounted for imaging in a Zeiss LSM 700 confocal microscope. 
T84 model human intestinal epithelial cells were prepared on 0.33-cm2 permeable filters 
and cultured in DMEM/F12 supplemented with 5% FBS. T84 cells were used after they had 
achieved a stable transepithelial resistance of >1,000 Ω·cm2. T84 cells were cultured in transwell 
chambers in a 24 well plate. Soluble AvrA-GST and eGFP or AvrA-eGFP NPs were 
administered to cells and cells were prepared as described for J774.A1 cells. Transwell 






2.2.5 Flow cytometry for quantitative assessment of nanoparticle 
J774.A1 cells were purchased from American Type Culture Collection and cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% (v/v) fetal bovine 
serum (FBS). SK-CO15 epithelial cells were cultured in DMEM with 10% FBS and 1% non-
essential amino acids. J774.A1 macrophages or SK-CO15 epithelial cells were plated at a density 
of 2x105 cells per well in a 24-well dish. After 14-16 hours of incubation, cell media was 
replaced with fresh media containing 300 µg/ml AvrA-eGFP NPs or soluble AvrA-GST an eGFP 
and incubated for 6 hours. Control cells were incubated with AvrA-eGFP NPs or soluble AvrA-
GST and eGFP at 4oC. Cells were washed twice with ice cold PBS, scraped or trypsinized, and 
fixed with 3.7% paraformaldehyde for 15 minutes at room temperature. Fixed cells were washed 
3 times by centrifugation with ice cold PBS and permeabilized with 0.25% Triton X-100 in PBS 
for 15 minutes at room temperature. Cells were rinsed three times in PBS and incubated with 
purified anti-AvrA antibody in 6% BSA and 10% FBS in PBS for 1h. After this, cells were 
washed 3 times with PBS and incubated with 20 nM Qdot 655 VIVID secondary antibody 
conjugate (Invitrogen) in 6% BSA in PBS for 1 hour. Cell were washed 3 times with PBS and 
analyzed in an LSR II flow cytometer (Becton Dickinson and Company). Positive events were 




2.2.6 Endocytic route of nanoparticles determined by endocytosis inhibitors 
J774.A1 cells were purchased from American Type Culture Collection and cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% (v/v) fetal bovine 




essential amino acids. J774.A1 macrophages were plated at a density of 2x104 cells per well in a 
24-well dish. After 14-16 hours of incubation, cell media was replaced with fresh media 
containing endocytosis inhibitors. Macropinocytosis was inhibited using 2 mM amiloride (MP 
Biomedicals, LLC). Caveolae-mediated endocytosis was inhibited using 300 µM genistein (TCI 
America). Clathrin-mediated endocytosis was inhibited using 20 µg/ml chlorpromazine (Alfa 
Aesar). Energy dependent endocytosis was inhibited by incubation at a 4°C (cells were also 
pretreated at 4°C for one hour prior to NP introduction).  
After 1 hour pretreatment with inhibitors, cell media was replaced with fresh inhibitor 
and AvrA-eGFP NPs or positive controls (Clathrin-mediated: transferrin-CF640R, Caveolae-
mediated: BSA-CF640R, Macropinocytosis: 10,000 MW Dextran-CF640R, all purchased from 
Biotium) suspended in PBS (50% v/v). 25 µg/ml of positive control or 300 µg/ml NPs were used. 
Cells were incubated for an additional 3 hours, then washed twice with ice cold PBS, scraped 
and resuspended in PBS. Cells were analyzed in an Accuri C6 flowcytometer and relative 
endocytosis was quantified as the ratio of mean fluorescence of the sample population to 
fluorescence of the control population (no particles given). 
 
 
2.2.7 Endosomal escape determined by hemolysis 
Washed red blood cells (RBCs) (Lampire Biological Laboratories) were diluted to a final 
concentration of 0.5% v/v in PBS solutions at pH 7.4, 6.5, and 5.4. NPs/soluble 
eGFP/mAvrA/AvrA were prepared at a volume of 100 µL at pH 7.4, 6.5, and 5.4 and incubated 
with an equal volume of the various RBC solutions at 37oC for 1 hour (final eGFP concentration 
= 150 µg/mL, final mAvrA/AvrA concentration = 12.5 µg/mL). After incubation, samples were 




supernatant was measured in a 96 well plate at an absorbance of 541nm. Relative hemolytic 
activity was calculated by subtracting the background absorbance of the various RBC solutions 
from the sample and normalizing to the hemolytic activity of 1% v/v Triton X-100.  
 
 
2.2.8 Endosomal escape visualized with lysosomal markers 
J774.A1 cells were purchased from American Type Culture Collection and cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% (v/v) fetal bovine 
serum (FBS). SK-CO15 epithelial cells were cultured in DMEM with 10% FBS and 1% non-
essential amino acids. 10,000 J774 macrophages were plated in an 8 well glass chamber 
overnight. eGFP/mAvrA/AvrA NPs/soluble were given to cells for a period of 6 hours (final 
eGFP concentration = 150 µg/mL, final mAvrA/AvrA concentration = 12.5 µg/mL). Cells were 
then washed twice with ice cold PBS and fixed with 3.7% paraformaldehyde for 15 minutes at 
room temperature. Cells were permeabilized with 1% Triton x-100/PBS for 15 minutes at room 
temperature and blocked with 1% BSA/PBS for 1 hour at room temperature. Lysosomes were 
labeled with 5ug/mL primary rat anti-LAMP1 antibody (BD Biosciences) overnight at 4oC 
diluted in blocking buffer. Cells were then incubated with 4ug/mL secondary TRITC goat anti-
rat antibody (Rockland) diluted in blocking buffer for 1 hour at room temperature. Nuclei were 
stained using 0.2 µM Hoechst 33342 (AnaSpec Inc.) for 15 minutes at room temperature. Cells 
with were washed 3 times with PBS (10 minutes per wash) between each step in the staining 
procedure. 50/50 PBS/glycerol solution was used a mounting media and samples were sealed 





2.2.9 Nanoparticle cytotoxicity determined by MTT and LDH 
The cytotoxicity of the capsules was evaluated using lactate dehydrogenase (LDH) assay. 
10,000 J774A.1 cells were plated in triplicate in a 96 well plate. 300ug/mL of NPs or sterile 
water were added to the wells and incubated for 6 hrs and 24 hrs. Controls for maximum LDH 
activity were also run according to the manufacturer’s instructions (Pierce LDH Cytotoxicity 
Assay, Thermo Scientific). 50 µl of each sample condition was transferred to a 96 well plate. 50 
µl of reaction mixture was added to each well and mixed. The reaction was protected from light 
for 30 minutes and 50 µl of stop solution was added to each well. The absorbance values were 
measured at 490nm and 680 nm using Biotek Synergy H4 Multimode plate reader (Biotek 
Instruments Inc) and reported as % cytotoxicity according to the manufacturer’s instructions. 
25,000 J774 macrophages were plated in a 96 well plate overnight. Media was exchanged 
for 300 µg/mL NPs for 3hr. After NP incubation, media was replaced with 100 µl of fresh media 
and 10 µl of MTT solution. Cells were incubated with MTT reagent for an addition 4 hours. 200 
µl of DMSO was then added to each well and wells were mixed vigorously to ensure cells were 




2.2.10 In vitro NF-kB luciferase reporter assay for intracellular AvrA activity 
HeLa cells were seeded at 6,000,000 cells/well in a 6-well plate and incubated overnight 
at 37oC. To prepare the transfection agent, 2 µg pGL4 plasmid (Promega) and 15 µL 
lipofectamine (Life Technologies) were added to 300 µL of serum free media (DMEM, ATCC) 
and incubated at room temperature for 5 minutes. The cell media was aspirated and the 




in DMEM was then added to the well. The transfection agent was incubated with the cells 
overnight at 37oC. Cells were then trypsinized and plated at 50,000 cells/well in a 96 well plate 
overnight in 1% FBS in DMEM. Cells were pretreated with NPs (300 µg/mL) for 4 hours and 
then stimulated with 20 ng/mL of recombinant human TNF-α (R&D Systems) for 1 hour. 
Afterwards, the media was aspirated and 50 µL BrightGlo reagent (Promega) and 50 µL serum 









2.3.1 Synthesis and characterization of AvrA nanoparticles 
The therapeutic approach described herein relies on the availability of active, soluble 
bacterial proteins and the ability to engineer the protein sequences for desired delivery 
properties. We cloned the genes of AvrA and a mutant form (mAvrA) into pGEX expression 
plasmids containing n-terminal glutathione S-transferase (GST) and c-terminal 6x-his tags using 
standard recombinant techniques to produce soluble AvrA-GST and mAvrA-GST fusion 
proteins. The mutant form contains a single cysteine substitution (C186A) that renders the 
acetyltransferase inactive and eliminates JNK inhibition and attenuates NF-κB suppressive 
activity.41 We expressed AvrA fusion proteins and a carrier protein, enhanced green fluorescent 





Figure 2.1: Purity of Ni-NTA purified recombinant eGFP and AvrA fusion proteins. 
Representative SDS-PAGE gel: lane 1 protein standard, lane 2 eGFP, lane 3 AvrA-GST, and 
lane 4 mAvrA-GST. Note the high purity levels achieved and in all cases a prominent band is 
observed at the expected molecular weight. 
 
We fabricated protein NPs by desolvating a solution of AvrA and eGFP protein by 
constant addition of ethanol while stirring (Figure 1.2).243 The resulting particles were cross-
linked with reducible 3,3´-dithiobis[sulfosuccinimidylpropionate] (DTSSP) to stabilize them 
during delivery (Figure 2.2). DTSSP contains a central disulfide bond that is sensitive to 
intracellular reducing conditions.244 By varying imidazole concentration during synthesis, we 
produced spherical particles with diameters of 125 +/- 25 nm and zeta-potential of -11.3 +/- 0.1 
mV in phosphate buffered saline (PBS) and -24.3 +/- 1.1 mV in 10 mM HEPES buffer. We 
selected this size in order to achieve mucosal barrier penetration and cellular internalization. 
Previous work has shown that the size, hydrophobicity and charge of particles play an important 
role in the transport of NPs in mucosa.228 In order to penetrate mucus, NPs must avoid adhesion 




slightly negative zeta-potential in the presence of physiological ion concentrations, which can 
prevent electrostatic interactions with negatively charged mucin fibers and thus, decrease 
adhesion to mucus. The size of AvrA-eGFP NPs is within the range of the interfiber spacing of 
mucin to allow the particles to diffuse through the mucus.228 
 
Figure 2.2: Chemical structure of 3,3’-Dithiobis(sulfosuccinimidylpropionate) (DTSSP, Thermo 
Scientific Pierce). DTSSP is a water-soluble, homo-bifunctional cross-linker that contains a 
central disulfide bond. DTSSP has two amine-reactive N-hydroxysulfosuccinimide esters at each 
side of a 12 Å spacer arm.  
 
Though smaller particles may have better delivery properties, they also contain less AvrA 
than large particles. The NPs contained approximately 316 AvrA molecules per particle. Real 
time imaging of a Salmonella model infection has shown that a different TTSS-secreted effector, 
SipA, mediates biochemical functions within minutes of infection at a concentration of 1000 
molecules/cell.245 Particles were fabricated from combinations of AvrA-GST or mAvrA-GST 
and eGFP to create fluorescent particles that could be visualized in specific experiments (Figure 
2.3). We substituted bovine serum albumin (BSA) for eGFP in particle formulations that 
required non-fluorescent particles but similar properties (99.7 +/- 23.1 nm in diameter, zeta 





Figure 2.3: Composition of AvrA-eGFP NPs. (a) Representative SDS-PAGE gel for eGFP and 
AvrA-GST NPs, and (b) representative western blot for eGFP NPs and AvrA-GST NPs, 
immunostained with anti-AvrA antibodies and showing native fluorescence of eGFP. 
 
 
2.3.2 Uptake and endocytosis of AvrA nanoparticles 
We sought to take advantage of endocytic uptake mechanisms of NPs containing AvrA, 
since the Salmonella TTSS is not feasible for AvrA delivery. We confirmed uptake of AvrA-
eGFP NPs by cultured J774A.1 macrophages or T84 polarized epithelial cells using confocal 
microscopy (Figures 2.4). T84 cells are a highly differentiated epithelial cell line that can 
recapitulate the barrier and uptake properties of the native epithelial monolayer.246 J774A.1 
macrophages serve as a model phagocytic cell and expectedly showed more eGFP 
fluorescence.247, 248 In the NP fabrication process, eGFP and AvrA are co-desolvated and 




The punctate spots seen in mid-cell optical sections clearly show delivery of NPs, while the lack 
of green fluorescence in the soluble eGFP images indicates very low uptake of soluble protein. 
 
Figure 2.4: Cellular uptake of AvrA particles. Confocal images of (A) T-84 and (B) J774A.1 
cells incubated with soluble AvrA and eGFP, or AvrA-eGFP NPs for 6 hours. Images are mid-
cell optical section overlays of eGFP fluorescence, nuclear Hoechst dye, and actin filaments 
labeled with rhodamine-phalloidin (scale bars 20 µm). 
 
Next, we used flow cytometry with anti-AvrA antibodies to quantify uptake of specific 
AvrA immunoreactivity, as well as eGFP fluorescence. At six hours, 420 times more J774A.1 
cells were positive for AvrA and eGFP when treated with NP AvrA-eGFP in comparison to cells 
treated with soluble AvrA and eGFP (Figure 2.5). SK-CO15 epithelial cells also internalized 
more NP AvrA-eGFP than soluble AvrA and eGFP in 6 hours. Though only ~10% of J77A.1 or 
SK-CO15 cells labeled positive for AvrA, significantly more J774A.1 cells labeled positive for 
eGFP (Figure 2.6). This could indicate that in macrophages the NPs are not completely 




signal is not dependent on particle dissociation. However, as described in the methods, the dose 
used for the uptake studies was larger than the dose for in vitro activity studies in order to have 
sufficient signal for imaging. The low signal also necessitated the use of a quantum-dot labeled 
secondary antibody to detect AvrA. This indicates AvrA is quite potent and we can detect 
functional activity at lower concentrations than we can detect the “physical presence” of AvrA in 
cells by fluorescence. Interestingly, eGFP and AvrA-eGFP particles had the same uptake in SK-
CO15 epithelial cell line but in J774A.1 macrophages AvrA-eGFP particles were taken up much 
more than eGFP only particles (Figure 2.6).  
 
Figure 2.5: Cellular uptake of AvrA particles. Flow cytometry quantification of soluble AvrA 







Figure 2.6: Uptake of AvrA-eGFP protein and NPs. Flow cytometry quantification of soluble 
AvrA and eGFP, eGFP only, and AvrA-eGFP NP uptake in SK-CO15 cells (light gray) and 
J774A.1 cells (dark gray). (* p<0.05) 
 
This is surprising, given that the particles with or without AvrA have the same size and 
zeta potential and that AvrA is a small fraction of the total protein in a particle (4% by mass). 
These data indicate that AvrA may play a role in uptake of the particles, though it seems to be 
cell type specific. YopJ, a close ortholog of AvrA, is another TTSS effector from Yersinia that 
shares sequence similarities with AvrA.249 YopJ is an anti-inflammatory and pro-apoptotic 
effector that is known to be cell selective; it induces apoptosis in macrophages and dendritic cells 
but not in endothelial cells or neutrophils.65, 250 AvrA could similarly exhibit some manner of 
specificity. AvrA has been shown to be differentially expressed depending on the organ location 
of the Salmonella infection66, suggesting potential specificity. Also, as a pathogenic protein, 
AvrA could contain pathogen associated molecular patterns (PAMPs) able to be recognized by 




on the surface of the NP can activate macrophages and increase endocytosis, leading to the 
difference in uptake seen between AvrA-eGFP and eGFP only NP. SK-CO15 cells are epithelial 
cells lacking PRRs. 
 
Figure 2.7: Cellular uptake of AvrA particles. Comparison of NP uptake by J774A.1 cells 
following pretreatment with the indicated drug. Asterisks indicate statistical significance of each 
cell type treated with inhibitor compared to untreated control. 
 
The route of NP uptake in J774A.1 cells was investigated by flow cytometry using the 
eGFP signal in the presence of endocytosis inhibitors (Figure 2.7). J774A.1 cells utilize primarily 
energy-dependent routes, as indicated by low uptake at 4°C. There was no strong preference 
toward a particular route, as inhibitors for macropinocytosis (amiloride), caveolae-mediated 
endocytosis (genistein), and clathrin-mediated endocytosis (chlorpromazine) all reduced NP 
uptake. Co-localization studies in J774A.1 cells of NPs with lysosomal marker anti-Lamp1, 
confirmed the route of uptake to be endosomal in nature and showed that the majority of NPs are 
found in lysosomes after 6 hours (Figure 2.8). However, the dose of NPs required for 





Figure 2.8: Colocalization of eGFP+AvrA NPs with endosomal/lysosomal markers. (A,B) eGFP 
NPs (green) were incubated with J774 macrophages for 6 hours and labeled with rab5 (red) for 
early endosomes. (C) eGFP NPs (green) were incubated with J774 and labeled for LAMP1 (red) 
for lysosomes. (D) Cells were incubated with eGFP+AvrA NPs and labeled with LAMP1. In all 
cases, cells were labeled for DNA (blue) with Hoechst. The merged column shows that NP 
colocalization (yellow) is only visible in lysosomal labeling and not visible in endosomal 





  Though colocalization studies with anti-Lamp1 indicated the majority of AvrA-eGFP 
NPs are endocytosed and traffic to lysosomes after 6 hours (Fig. 2.8), the detection of single 
AvrA-GST protein in cell lysates and the functional AvrA activity described below demonstrate 
that some AvrA protein does reach the cytosol. Though it is difficult to pinpoint endosomal 
escape mechanisms for most NPs, there are several features of AvrA particles that could 
contribute to their escape. One contribution could be from osmotic pressure changes that may 
occur as the crosslinks reduce and particles break up into soluble protein. Reducible polyarginine 
DNA nanocarriers have been shown to have higher transfection efficiency than those that are not 
reducible or when disulfide reduction was inhibited.251 Another possible mechanism is 
membrane destabilization due to cationic interactions and an osmotic buffering effect by 
protonation of the 6x-histadine tags on eGFP and AvrA-GST.252 It is also possible that AvrA 
itself could have endolytic properties, as there are a variety of bacterial pathogens that produce 
toxins or effectors that contain domains that assist in endosomal escape by different 
mechanisms.193 Hemolysis assays showed that pure, soluble AvrA-GST was significantly lytic 
with increasing concentration from 10 to 1000 µg/mL and at higher concentrations lysis was 
increased at neutral pH compared to acidic conditions (Figure 2.9). Considering a single particle 
in a 200 nm endosome, the AvrA concentration is estimated to be higher than 1000 µg/mL. This 
suggests AvrA may have endosomal escape properties prior to acidification. However, when the 
hemolytic activity of mixtures of soluble eGFP and AvrA was assessed, as would be found from 
a disassembled particle, the lytic activity was completely abolished (Figure 2.10). This suggests 
that soluble eGFP interferes with any lytic property of AvrA. Interestingly, intact AvrA-eGFP 
NPs did exhibit some lytic activity, at neutral and slightly acidic pH. NPs made only of eGFP or 




pH. This data suggests that intact AvrA-eGFP NPs could contribute to destabilization of 
endosomal membranes at early stages of acidification. It also suggests more generally that AvrA 
in AvrA-eGFP NPs has some interaction with cell membranes, in agreement with the observation 
in Figure 2.6 that AvrA-eGFP NPs are internalized by macrophages more than eGFP NPs. 
 
Figure 2.9: Hemolysis of soluble AvrA-GST at different concentrations at pH. Relative 
hemolytic activity is normalized to a positive control, 1% v/v Triton X-100, after subtracting 






Figure 2.10: Hemolysis of eGFP (150ug/mL) with or without AvrA or mAvrA (12.5ug/mL) as a 
function of pH. All soluble samples, as well as pH 5.4 NP samples, exhibited hemolysis below 
background. Relative hemolytic activity is normalized to a positive control, 1% v/v Triton X-
100, after subtracting background absorbance at 561nm. (** p<0.005) 
 
 
2.3.3 In vitro NF-kB activity and cytotoxicity of AvrA nanoparticles 







Figure 2.11: Cytotoxicity of AvrA-eGFP NPs. (a) Lactate dehydrogenase (LDH) activity of 
J774.A1 cells incubated with NP formulations of eGFP or AvrA-eGFP for 6 or 14 hours. (b) Cell 
viability determined by methyl thiazole tetrazolium (MTT) assay for J774.A1 cells treated with 
soluble or NP formulations of eGFP or AvrA-eGFP for 3 hours.	 
 
AvrA has been shown to inhibit JNK phosphorylation and IκB degradation by 
transfection and transgenic approaches.41, 47 Experiments with AvrA-eGFP NP preparations 
applied to the apical surface of polarized T84 monolayers for 3 hours, to allow particle 
internalization and dissociation, were successful in partly suppressing both TNF-α induced JNK 
activation and IκB degradation41. AvrA NPs show stabilization of Iκβα after 30 minutes with 
levels reaching the pre-stimulation levels by 60 minutes. AvrA is hypothesized to act on a distal 
event in the NF-kB pathway downstream of P-Iκβα.41 Though Iκβα still is phosphorylated, this 
does not lead to degradation of Iκβα, thereby preventing NF-kB release and transcription of 
inflammatory signals. For this reason, levels of P-Iκβα increase over time in the presence of 
TNF-α and AvrA NPs as Iκβα accumulates due to reduced degradation. JNK inhibition by AvrA 




did not inhibit JNK47. The ability of AvrA NPs to suppress NF-κB activity was confirmed by a 
luciferase gene reporter assay (Figure 2.12). Partial suppression of NF-κB activity was observed 
with mAvrA NPs. AvrA, has been shown to also exhibit deubiquitinase activity in the NF-κB 
pathway that is not entirely eliminated by the C186A mutation.253  
 
Figure 2.12: AvrA NPs inhibit inflammatory signaling. AvrA NPs were applied for 4 hrs prior 
to TNF-a stimulation. NF-kb reporter gene assay (*p<0.05 compared with TNF-α control 
samples, ** p<0.01 compared with TNF-α control samples). 
 
Interestingly, mutant AvrA particles also showed significant activity, suggesting the 
therapeutic enzymatic activity of AvrA in this model is not abolished with a single mutation in 
the acetyltransferase active site. Mutant AvrA partial activity is reported in literature and seen in 
the in vitro activity data (Figure 2.12), possibly because the deubiquitinase activity in the NF-κB 
pathway is not entirely eliminated by the C186A mutation.253 Indeed, many, if not most TTSS 




activities in AvrA may account for partial activity seen in vivo. AvrA, specifically, has 
deubiquitinase activity in the NF-κB pathway that is not completely eliminated by the 
mutation.253 A second active site, an SH2-like domain, is also present in AvrA and Yersinia 
ortholog YopJ.254 Mutation of this D/E-X-E active site reduces YopJ anti-inflammatory function, 
and is expected to have a similar function in AvrA. This domain should be unaffected by the 
C186A mutant used in these studies and so its function would remain intact. We have also seen 
partial function of NPs made from the same mutant of YopJ, in agreement with multiple domains 
responsible for bioactivity.256 
The protein NP platform is highly adaptable to a variety of biological molecules and 
chemistries. NP formation, stabilization, and targeting ligands can be independently modified to 
suit the biological delivery requirements of different diseased tissues and routes of 
administration. For example, AvrA NPs could also be used in other models of inflammation that 
do not require systemic access, such as in the joints, airways, skin, or eyes. In this work both 
BSA and eGFP were used as carriers for the AvrA and in either case, AvrA was successfully 
delivered and retained its function. The versatility of the protein NP would allow use of 
recombinant human serum albumin (HSA) as a carrier in future human clinical applications as it 
is more physiologically benign and FDA approved. While AvrA was chosen as a model 
immunosuppressive protein for construction into NPs, this approach could be applied to other 
proteins. Orthologous acetyltransferases (YopJ, VopA, AopP) have been detected in a variety of 
bacteria that associate intimately with eukaryotic hosts, and these effectors exhibit extended 
activity against a wider spectrum of MAPKs. Our lab and others have been studying these related 
effectors that have variable effects on MAPK and are more potently immune suppressive, but 




a potentially vast repository of biochemical activities relevant to manipulation of eukaryotic 
inflammatory signaling, and exploitation of bacterial virulence proteins in yeast and mammalian 
immune cells has been explored as a synthetic biology approach.257 However, this method is not 
limited to bacterial proteins or single types of proteins. Combination therapies of bacterial 
proteins and human cytokines or small molecule anti-inflammatory agents, for example, may 
have value in future immunological therapeutics.  
 
 
2.3.4 In vivo activity of AvrA nanoparticles 
To detect particle uptake in vivo, we used direct transrectal instillation of AvrA-eGFP 
particles into both intact and damaged/inflamed murine colons. In tissues evaluated post 
instillation, eGFP was detected in the extracellular mucus layer of the epithelial cells by anti-
eGFP (Figure 2.13). Intracellular eGFP uptake was seen within epithelial cells by 4h in apical 
cells and in the base of crypts (Figure 2.14). eGFP positive cells were seen in the lamina propria 
(Figure 2.14) and in F4/80 positive macrophages (Figure 2.14). NP uptake in healthy tissue 
indicates that NPs are able to penetrate healthy, fully intact mucus and could potentially be used 
as a protective agent to prevent the spread of inflammation. We were unable to detect AvrA 
immunoreactivity in vivo, likely due to the small amount of AvrA taken up. Based on the 
colocalization of eGFP and anti-AvrA signals from in vitro flow cytometry NP uptake 
experiments, we conclude from the anti-eGFP fluorescence that AvrA-eGFP NPs are taken up 
and AvrA is present with eGFP. The in vivo images indicate that these particles effectively 







Figure 2.13: Time course of NPs uptake in vivo. Particles were instilled transrectally and imaged 
at (a) 0.5 hour, (b) 1 hour, (c) 2 hours, (d) 3 hours. Particle uptake is marked by eGFP 
fluorescence (green). Epithelial cells are counterstained with beta-catenin (red) (40x 






Figure 2.14: Time Mucosal uptake of AvrA-eGFP (12 μg eGFP) particles in healthy murine 
colonic surface epithelium (a), crypts (b), lamina propria (c), and macrophages (F4/80+) (d) 
imaged by confocal microscopy (scale bars 20 μm). Particles were instilled transrectally and 
imaged after 4 h. Particle uptake is marked by anti-eGFP fluorescence (green). Epithelial cells 
are counterstained with beta-catenin (red in (a−c)) and macrophages stained with F4/80 (red in 
(d), yellow indicates colocalization of eGFP and F4/80+). *Experiment was performed in the 
laboratory for Dr. Andrew Neish at Emory University. 
 
Dextran sodium sulfate (DSS) colitis is another in vivo model where the chemical irritant, 
supplied in drinking water, results in epithelial erosions and subsequent inflammation in the 




day prior and 1 day post initiation of DSS (Figure 2.15), and as a therapeutic design, 
administered 7 days post initiation of DSS after clinical symptoms have become manifest (Figure 
2.15). In both experimental designs, suppression of clinical indices and scores of colonic 
inflammation were observed. From these experiments we conclude that sufficient quantities of 








Figure 2.15: Anti-inflammatory effect of AvrA on dextran sodium sulfate (DSS)-induced colitis. 
(a) Clinical disease activity index and (b) histological scoring of 5 mice per indicated condition 
receiving two injections (intrarectal) of NPs (900 ng AvrA per injection) while subjected to DSS 
challenge for 7 days. (c) Representative colon gross pathology from mice treated as indicated in 




activity index and (f) histological scoring of 5 mice per indicated condition treated once with 
NPs (900 ng AvrA) after DSS-induced colitis (*p < 0.05). *Experiments were performed in the 
laboratory of Dr. Andrew Neish at Emory University. 
 
IBD results from aberrant mucosal immune activation, often in the context of genetic 
susceptibility, resulting in the influx of acute and chronic inflammatory cells into the mucosa. 
Both the overlying epithelial monolayer and the underlying immune cells of the lamina propria 
possess the ability to initiate inflammatory reactions during injury.258 In our murine experiments, 
restricted to transrectal delivery of NPs into the distal colon, both surface epithelial and 
monocytic cells in the lamina propria took up NP formulations of AvrA under control and colitic 
conditions. AvrA particles potently suppressed histologic inflammation and clinical injury in 
several commonly used in vivo models of colitis. It is widely known that there is not a perfect 
model of IBD. In our studies, we utilized chemical models of acute/self-limited inflammation 
with DSS and TNBS that occur even in the absence of a functional adaptive immune system. 
Thus, our data demonstrates an inflammatory suppressive role outside of adaptive regulatory 
mechanisms. We speculate that use of AvrA NPs in the treatment of a chronic model of IBD, 
such as IL-10 knockout259 or T-bet and RAG2 double knockout260, would lead to similar results 
of suppression of inflammation markers and disease activity scores because the JNK and NF-κB 
targets of AvrA are highly conserved inflammatory signaling molecules. Though complications 
arising from tissue restructuring, such as neoplasia and fibrosis, would likely not be reversed by 
AvrA NPs, further damage could be prevented and a reversal of symptoms may be observed. To 
make these NPs clinically relevant, oral delivery is necessary. Future work will entail 
encapsulation of NPs and oral delivery that will allow AvrA-eGFP NPs access to Peyer’s patches 
and other components of the gut associated lymphoid tissue (GALT) resident in the distal ileum. 








Enteric bacteria have coevolved with humans to develop specific effector proteins 
capable of immunomodulation. We engineered one such protein, AvrA, to form protein NPs, 
enabling intracellular delivery of AvrA in the absence of Salmonella. AvrA NPs inhibited 
inflammatory pathways in vitro and reduced inflammation in murine colitis models, indicating 
their potential as a treatment for IBD. Future work could expand the protein NP platform to other 




















Crohn’s disease (CD) and ulcerative colitis (UC), the two major forms of inflammatory 
bowel disease (IBD), are chronic inflammatory disorders of the gastrointestinal tract resulting 
from inappropriate and amplified mucosal immune response to the otherwise normal microbiota 
existing in the gut1, 2. The CDC estimates that approximately 3.1 million people in the US are 
living with IBD4 and there is an increasing global prevalence6 of the disease. Patients are treated 
with a combination of locally acting anti-inflammatory small molecules9, 10, 11, systemic 
corticosteroids, monoclonal antibodies12, and surgery. Although these treatments can be 
effective, they have specific windows of efficacy10, long-term side effects13, 14, 15, and risk of 
infection9, 16 associated with them. 
The human mucosal immune system has evolved microenvironments favoring 
commensal bacteria while inhibiting pathogenic bacteria261, 262. Some pathogenic bacteria are 
able to overcome these evolutionary mechanisms by modulating host response through the 
injection of bacterial effector proteins via a needle-like type-3 secretion system (T3SS)38, 263. One 
of these bacterial effector proteins is AvrA, from Salmonella.39, 40 AvrA is an enzyme that 
functions in the cytosol to acetylate key serine and threonine residues on MKK4/7, thus 
inhibiting phosphorylation and preventing signaling in the JNK pathway and blocking 
apoptosis47, 48, 49. It has also been reported that AvrA indirectly deubiquitinates Iκβα by an 
unknown mechanism, stabilizing phosphorylated-Iκβα (p-Iκβα) and inhibiting further 




with dual anti-apoptotic and anti-inflammatory enzymatic function can be utilized to ameliorate 
gut inflammation52. Our previous work demonstrated that AvrA delivered by protein 
nanoparticles (NPs) replaces the need for delivery by Salmonella T3SS. Protein NPs are 
synthesized by desolvation and stabilized with a reducible crosslinker designed to release soluble 
protein in the reducing environment found in the cytosol. Protein NPs increase cellular 
internalization of proteins compared to soluble243. Protein NPs also have high protein loading, 
are capable of penetrating the mucus, and can passively target inflamed tissue199, 200, 236, 264. AvrA 
NPs were shown to decrease inflammatory markers in vitro, and reduce symptoms of colonic 
inflammation in two murine colitis models following transrectal delivery51.  
Transrectal delivery is undesirable for patients and also limits delivery to the distal 
portion of the colon, both of which hinder the clinical potential of AvrA NPs. Therefore, we 
sought to engineer an oral delivery vehicle to maximize therapeutic potential. The biggest 
obstacle to oral delivery of proteins is the harsh environment found in the stomach, where low 
pH, digestive enzymes, and mechanical forces act to break down proteinaceous materials for 
digestion195, 199. Therapeutic soluble proteins have been co-delivered with protease inhibitors to 
prevent enzymatic degradation and permeation enhancers to facilitate transport across mucus and 
through the epithelium196, 197. These methods have traditionally been used for systemic delivery 
of proteins, though chronic use of these inhibitors and enhancers can lead to severe side 
effects198. Conjugating proteins with cell penetrating peptides or mucoadhesive polymers can 
increase targeting and minimize off-target effects. However, these methods still suffer from low 
penetration and bioavailability from natural mucus turnover198. To overcome these challenges, 
localized intestinal delivery of protein therapeutics has typically been accomplished by NPs or 




passively target inflamed tissue202, enhance mucus penetration, and membrane permeation203. 
MPs can provide a larger depot for protein therapeutics that can be engineered to be stimulus 
responsive204. NPs and MPs can improve protein stability and be engineered to target specific 
regions of the gastrointestinal tract199. Nanoparticles-in-microsphere oral system (NiMOS)205, 
combines these two particulate system in a unique approach for oral gene delivery206, 207. Gelatin 
NPs encapsulating plasmid DNA were then encapsulated in a poly(epsilon-caprolactone) MPs 
and shown to transfect the small intestine and colon of rats. NiMOS has the advantages of both 
NP and MP delivery systems as NPs were capable of penetrating the mucosal barrier and MPs 
protected NPs from enzymatic degradation until they reached the absorbing epithelium. Adapting 
NiMOS for protein therapeutics can provide a novel method for localized intestinal delivery. A 
NiMOS for proteins would need to provide a more stringent pH protective capability as proteins 
are more sensitive than DNA to pH changes that can cause denaturation.  
Alginate and chitosan are two natural polysaccharides generally regarded as safe (GRAS) 
by the Food and Drug Administration (FDA) that have been used as NPs or MPs for oral 
delivery of insulin208, 209, 210, BSA211, 212, hemoglobin213,  probiotics214, 215, and cells216, 217. 
Alginate can form hydrogels under mild gelation conditions ideal for protein encapsulation218. A 
chitosan coat can be used in conjunction with alginate hydrogels to remedy the problems of drug 
leakage219. Alginate hydrogels shrink at gastric pH and the complementary electrostatic 
properties of anionic alginate and cationic chitosan allow interpolymeric associations 
strengthened by the protonation of chitosan amine groups at low pH. At intestinal pH, which 
ranges from pH 6 to pH 7.5 depending on location in healthy individuals however lower in IBD 




release of encapsulated cargo. This pH-response trigger should allow alginate/chitosan hydrogels 
to protect protein NPs at gastric pH and then release them at intestinal pH.  
In this chapter, we engineered alginate/chitosan hydrogel MPs encapsulating protein NPs 
using a flow focusing microfluidic device. The NPs in MPs delivery system was able to protect 
enhanced green fluorescent protein265 (eGFP) function in simulated gastric fluid (SGF) and 
subsequently release functional eGFP NPs in simulated intestinal fluid (SIF). In vivo, eGFP 
delivered orally by NPs in MPs was detected in intestinal epithelial cells of healthy and sick 
mice. Furthermore, alginate/chitosan MPs were effective in delivering AvrA NPs to reduce 
clinical and histological indices in a murine dextran sulfate sodium (DSS)-induced colitis model. 
Altogether these data show the potential of using alginate/chitosan MPs for the gastric passage 
and intestinal delivery of protein NPs. 
 
3.2 Experimental Methods 
 
3.2.1 Production of recombinant proteins 
Recombinant proteins were produced as described previously51. Briefly, the eGFP gene 
in the pPROTet plasmid (Clontech Laboratories) was a generous gift from Dr. Andreas 
Bommarius and was expressed constitutively for 12 hours in BL21 Escherichia coli with 34 
µg/mL of chloramphenicol (VWR) in 2XYT media. eGFP was purified with Ni-NTA agarose 
(Qiagen) following the manufacturer’s native imidazole purification protocol. AvrA in the 
pGEX-4T-2 plasmid (GE Lifesciences) was expressed in AFIQ Escherichia coli with 34 µg/mL 
of chloramphenicol and 200 µg/mL of ampicillin (VWR) in 2XYT media. AvrA bacterial 
cultures were grown to optical density (O.D.) of 0.7 at 37°C and induced with 0.4 mM isopropyl 




4B (GE Healthcare) following manufacturer’s protocol and then purified with Ni-NTA agarose 
following manufacturer’s native imidazole purification protocol. Purified proteins were 
concentrated using 10 kDa MWCO centrifugal ultrafiltration devices (Millipore) to eGFP 
concentration ~12mg/mL and AvrA concentration ~1mg/mL in elution buffer (250 mM 
imidazole, 50 mM sodium phosphate monobasic, 300 mM sodium chloride, pH 8) determined by 
Nanodrop 2000c (Thermo Fisher Scientific) using MW = 26.95 kDa and e = 61000 cm-1 M-1 for 
eGFP and MW = 59.84 kDa and e = 60910 cm-1 M-1 for AvrA. 
 
3.2.2 eGFP and AvrA NP synthesis 
50 µl of eGFP was added to a glass vial and the volume was completed to 100 µl with 
AvrA or elution buffer. The mixture was stirred at 700 rpm and desolvated with 400 µl of 200 
proof ethanol with a dropwise addition rate of 1 mL/min. 64 µl of 5 mg/ml DTSSP (Pierce) 
(2.2:1 DTSSP:lysine mole ratio) was added and the mixture was stirred for 90 minutes. The 
particles were then centrifuged at 500 x g for 5 minutes, supernatant removed, and the particle 
pellet was resuspended in 0.5 mL of sterile PBS or sterile water. The NPs were sonicated using a 
sonicate probe (1s on, 3s off, 50% amplitude, 1 minutes) on ice prior to DLS measurement.  
 
3.2.3 NP size and chacterization 
Average NP size was characterized using Zetasizer Nano ZS90 (Malvern Instruments 
Ltd.) with a minimum of three batches of each NP type with three replicates of 10 measurements 
using the following settings: proteins setting for NP detection and manufacturer PBS settings as 
the dispersion medium. NP z-potential was determined by measuring the electrophoretic 




determined using a BCA assay (Pierce) following the manufacturer’s protocol. NP composition 
was determined using gel electrophoresis by heating 50 µg of NPs in sodium dodecyl (lauryl) 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer (50 mM Tris-Cl, pH 6.8, 
2% SDS, 100 mM DTT, 0.1% bromophenol blue, 10% glycerol) for 5 minutes at 95°C and 
loading into a 12% SDS polyacrylamide gel. After SDS-PAGE, proteins were transferred to a 
nitrocellulose membrane and immunolabelled with Alexa-Fluor 488 conjugated penta-his 
antibody (Qiagen). Nitrocellulose membranes were then imaged with a Typhoon FLA 9500 (GE 
Healthcare Life Sciences). 
 
 
3.2.4 Microfluidic device preparation 
A silicon wafer master was designed and fabricated using multi-layer soft lithography 
techniques and was a generous gift of Emily Jackson and Professor Hang Lu. 
Polydimethylsiloxane (PDMS) (Sylgard 184, Dow Corning) devices were prepared by 
thoroughly mixing base polymer to cross-linker at a ratio of 10:1. The mixture was degassed in a 
vacuum chamber for an hour. PDMS was poured onto the master wafer and cured overnight at 
90°C. After curing, the PDMS was cut from the master wafer molds and inlet and outlet access 
channels were punched with 18 gauge needles. The PDMS devices were plasma treated (PDC-
32G plasma cleaner) and bonded onto glass slides and stored at room temperature until further 
use. 
 
3.2.5 Alginate/chitosan MPs encapsulating protein NPs  
4% w/v low viscosity alginate (Protanal LF 200FTS, FMC Biopolymers) was dissolved 




alginate solution until the final alginate concentration was 2% w/v (dispersed phase). The 
dispersed phase was loaded into a syringe equipped with a 20 gauge needle. 1% Span 80 (TCI 
America) in mineral oil (VWR) was used as the continuous phase and loaded into a syringe with 
a 20 gauge needle. The syringes placed on a syringe pump (NE-1000, New Era Pump Systems, 
Inc.) and the needles were connected to the microfluidic device. The flow rate for the aqueous 
phase was 10 µl/min and the flow rate of the oil phase was 50 µl/min. The collection bath 
contained 0.5% chitosan (85% deacetylated, Alfa Aesar) and 0.1% CaCl2 (VWR) dissolved in 
pH 5.5 water under constant stirring. Alginate/chitosan MPs were collected afterwards and 
centrifuged at 500 x g. The MPs were washed with DI water until no more oil was visually 
present and stored in DI water until further use. 
To view chitosan coating, eGFP NPs were added to the alginate disperse phase and 
mRFP NPs were added to chitosan collection bath. Crosslinked MPs were collected, washed 
with DI water and sandwiched between two 24 x 60 mm coverslips. Images were taken on Zeiss 
LSM 700 confocal. 
 
3.2.6 Optical microscopy 
200 µL of chitosan coated alginate MPs were sandwiched between two 24 x 60 mm 
coverslips (VWR Superslip) and phase contrast and fluorescent images were taken using a Zeiss 
Axio Observer Z1 inverted microscope. At least 100 microparticles were imaged and diameter 





3.2.7 eGFP NP pH recovery 
100 ug of eGFP NPs were resuspended in 1 mL of PBS. Hydrochloride acid (HCl) was 
added to each mixture until the desired pH was reached. Afterwards, the mixtures were incubated 
at room temperature for 30 minutes. The fluorescence was measured using a Bio-Tek Synergy 2 
plate reader. To recover fluorescence, sodium hydroxide (NaOH) was added to each solution 
until the pH = 7.4. Afterwards, the mixtures were incubated at room temperature for 30 minutes 
and the fluorescence was re-measured using a Bio-Tek Synergy 2 plate reader. 
 
3.2.8 In vitro simulated fluid assay 
Simulated gastric fluid and intestinal were made according to updated recipes266. 50 mL 
of either gastric fluid or intestinal fluid was incubated with 4 mg of MPs containing 200 ug of 
eGFP NPs at 37°C under constant rotation. At defined time points, the solution was centrifuged 
at 500 x g and 500 µL of supernatant was collected and replaced with 500 µL of fresh simulated 
fluid. For experiments requiring intestinal incubation after gastric incubation, the gastric pellet 
was washed two times with PBS in order to neutral remaining gastric buffer. The collected 
supernatants were then analyzed for fluorescence in a plate reader or BCA assay was used to 
determine protein concentration. 
 
3.2.9 Detection of protein NP uptake in cells 
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10% (v/v) fetal bovine serum (FBS). Media was also supplemented with 1% 




cells were plated at a density of 100,000 cells per well in a 24-well dish. After 14−16 h of 
incubation, cell medium was replaced with media containing 200 µL MP released eGFP NPs or a 
fluorescent equivalent of eGFP NPs that have not undergone encapsulation and 200 µL of media 
incubated for 6 hr. Cells were washed twice with ice cold PBS and trypsinized. Cells were 
resuspended in 0.4% Trypan Blue (Corning) to quench non-internalized green fluorescence267 
and analyzed in an LSR II flow cytometer (Becton Dickinson and Company).  
 
3.2.10 Ex vivo small intestine NP uptake 
Care of experimental animals was performed in accordance with Emory University 
IACUC institutional guidelines. C57BL/6J mice were sacrificed and small intestine was removed 
(n = 3). 10 cm of small intestine was cut and filled with 500 µL of MP released eGFP NPs in a 
modified everted gut sac model268 or “intestinal sausage casing” tied with dental floss. The 
intestine was then submerged in DMEM with 10% FBS overnight at 37°C. Intestines were then 
cut longitudinally and washed with PBS twice before being fixed in 3.7% paraformaldehyde for 
30 minutes at room temperature. Fixed colonic ex vivo small intestine sections were stained for 
cytoskeletal and nuclear markers. Actin was labeled with 0.165 µM phalloidin-rhodamine 
(Biotium) and the nucleus was stained using 0.2 µM Hoechst 33342 (AnaSpec Inc.) for 30 
minutes at room temperature. Cells with were washed 3 times with PBS (10 minutes per wash). 
50% glycerol in PBS was used a mounting solution and samples were sealed with a coverslip and 





3.2.11 In vivo small intestine NP uptake 
C57BL/6J mice were fasted overnight and empty MPs (4 mg), unprotected eGFP NPs 
(200 µg), and eGFP NPs in MPs (4 mg MPs, 200 µg NPs) were administrated to mice via oral 
gavage needles (Cadence Science), in a total volume of 200 µL (n = 5). After 4 hours, mice were 
sacrificed. Small intestines and colon were removed and embedded in O.C.T. compound (Tissue-
Tek) and snap frozen in isopentane on dry ice. 20 µm frozen section were cut using CryoStar 
NX70 Cryostat (Thermo) and mounted on glass slides. Swiss roll colonic frozen sections in 
optimal cutting temperature (OCT) solution were cut using the CryoStar NX70 Cryostat 
(Thermo) into 20 µm sections. A PAP pen (Thermo) was used to draw circles around the 
sections. The sections were fixed with 3.7% paraformaldehyde for 15 minutes and washed in a 
slide holder dunking into PBS 10 times and left to soak for 10 minutes. The cell surface was 
immunostained with 100 ng/mL rabbit anti-β-catenin (Proteintech) and eGFP was labeled with 
50 ng/mL rat anti-GFP (Biolegend) antibodies. 100 ng/mL of sheep rhodamine conjugated anti-
rabbit IgG (Rockland) was used as β-catenin secondary antibody. 50 ng/mL of goat ATTO 647N 
conjugated anti-rat IgG (Rockland) was used as eGFP secondary antibody. Nuclei were stained 
with Hoechst 33342 (AnaSpec Inc.). Intestinal uptake of protein NPs was imaged using a Zeiss 
LSM 710 confocal laser scanning system. Image analysis was performed using Matlab to 
quantify the number of red and green pixels. A 2D maximum projection confocal image of 
various sections of the colon was converted into an array of 512 x 512 pixels with each pixel 
containing red, blue, and green values that range numerically from 0 to 255. A 20% threshold (of 
the maximum pixel value) chosen as a cutoff point. Red, blue, and green pixel intensities about 
the threshold returned a true value and pixel intensities below the threshold returned a false 




pixels. Normalized green pixels count from empty MPs were taken as the baseline compared 
with unprotected eGFP NPs and eGFP NPs in MPs. 
 
3.2.12 In vivo DSS colitis mouse model 
Dextran sulfate sodium (36000-50000 MW; MP Biomedicals) colitis was induced by 
giving 3% w/v DSS in autoclaved MilliQ water as drinking water and allowing mice to drink ad 
libidum for 10 days. Treatment groups (n = 5) of PBS, 200 µg of AvrA NPs (16 µg of AvrA), 4 
mg empty MP, 4 mg eGFP NPs in MPs (200 µg of NPs), and 4 mg AvrA NPs in MPs (200 µg of 
NPs, 16 µg of AvrA) were administrated via an oral gavage needle. Total volume of gavage was 
200 µL. Mice were gavaged once a day for 5 days prior to introduction of DSS. Afterwards, 
mice were gavaged daily for the 10 day duration of the DSS in the water supply. Disease activity 
was monitored daily. Disease activity index was calculated as the sum of the scores of stool 
consistency (0: hard, 2: soft, 4: diarrhea), fecal occult blood using Hemoccult Sensa (Beckman 
Coulter) (0: negative, 2: positive, 4: macroscopic) and weight loss (0: <1%, 1: 1-5%, 2: 5-10%, 
3: 10-20%, 4: >20%). Disease score was calculated as the average of these three parameters. 
After the 10th day on DSS, mice were sacrificed and colons were removed and fixed in 3.7% 
formalin for 1 day in a “swiss roll” orientation then transferred to 70% ethanol for 3 days before 
being embedded in paraffin. Caecum was removed, washed with PBS, and stored as whole tissue 
in -80°C. 
Paraffin embedded sections were deparaffinized using the Autostainer XL (Leica), 
circled with a PAP pen (Thermo) and immunostained with 100 ng/mL rabbit anti-β-catenin 
(Proteintech) and 50 ng/mL rat anti-GFP (Biolegend) antibodies. 100 ng/mL of sheep rhodamine 




goat ATTO 647N conjugated anti-rat IgG (Rockland) was used as eGFP secondary antibody. 
Nuclei were stained with Hoechst 33342 (AnaSpec Inc.). Inflamed colonic uptake of protein NPs 
was imaged using Zeiss LSM 710 confocal laser scanning system. 
 
3.2.13 MPO assay 
Caecum was homogenized with a Polytron PT 1200E handheld homogenizer in ice-cold 
potassium phosphate buffer (50 mmol/l K2HPO4 and 50 mmol/l KH2PO4, pH 6.0) containing 
0.5% hexadecyltrimethylammonium bromide (Sigma-Aldrich) and then centrifuged at 17500 x g 
for 15 minutes. Supernatants were collected and added to 1 mg/mL o-dianisidine hydrochloride 
(Sigma-Aldrich) and 0.0005% H2O2, and the change in absorbance at 450 nm was measured on a 
Bio-Tek Synergy 2 plate reader. One unit of MPO activity was defined as the amount that 




Colonic swiss rolls embedded in paraffin were cut using Microm HM 325 Rotary 
Microtome (Rankin Biomedical) into 10 µm slices, deparaffinized, and stained with hematoxylin 
and eosin using Autostainer XL (Leica). Photographs were taken using a Nikon Eclipse E600 w/ 
Q-Imaging with 2x, 10x, 20x, and 40x objectives. Histological examination was performed by 
two independent observers on hematoxylin−eosin slides of paraffin colon sections. Histology 
score was assessed for severity of inflammation (0: none, 1: slight, 2: moderate, 3: severe), PMN 
infiltration/HPF (0: <5, 1: 5−20, 2: 21−60, 3: 61−100, 4: >100), depth of injury (0: none, 1: 




2/3, 3: only surface epithelium intact, 4: entire crypt lost), and adjusted to tissue involvement by 
multiplication of percentage factor (x1: 0−25%, x2: 26−50%, x3: 51−75%, x4: 76-100%)269. 
 
3.2.15 Statistics 
Significance was assessed by a one-way ANOVA or Student’s unpaired t-test at a 
significance level of p < 0.05. All data shown is representative of at least three independent 
measurements unless indicated otherwise. 
 
 
3.3 Results and Discussion 
 
3.3.1 Synthesis, characterization, and stability of protein NPs 
AvrA was expressed as a fusion protein containing a N-terminal glutathione S-transferase 
(GST) tag to improve AvrA solubility270 and a C-terminal 6x-His tag for purification. Protein 
NPs were synthesized by desolvating either a solution of eGFP or eGFP and AvrA with ethanol 
under constant stirring162, 243 (Figure 3.1) to make eGFP NPs or eGFP+AvrA NPs, shortened to 
AvrA NPs for the rest of this report. The nanoclusters formed were crosslinked with reducible 
3,3’-dithiobis-[sulfosuccinimidylpropionate] (DTSSP) to stabilize them. DTSSP was chosen 
because it contains a disulfide bond sensitive to the reducing conditions found in the cytosol271. 
Dynamic light scattering (DLS) showed eGFP NPs had a diameter of 270 ± 55 nm, 
polydispersity index (PDI) of 0.352 ± 0.153, and z-potential of -11.6 ± 0.9 mV in phosphate 
buffered saline (PBS). When AvrA was co-desolvated with eGFP to make AvrA NPs, the 
properties were similar with NP diameter of 281 ± 52 nm, PDI of 0.327 ± 0.074, and z-potential 




(Figure 2.3). We estimate that each AvrA NP contains on the order of 5,000 molecules of AvrA 
and 100,000 molecules of eGFP based on the volume of a spherical NP and the theoretical 
volumes of the proteins based on their molecular weight and average protein partial specific 
volume272. Using eGFP as a carrier for AvrA in the NP allows for fluorescent tracking of the NPs 
and eGFP fluorescence serves as a proxy for protein activity.  
  
Figure 3.1: Synthesis and Characterization of Protein NPs in MPs. Schematic representation of 
AvrA NP desolvation, NP loading into alginate droplets via flow focusing microfluidic device, 
and NPs in MPs simultaneous crosslinking and coating with calcium and chitosan.  
 
Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) containing digestive 
enzymes were incubated with eGFP NPs to test the ability of NPs alone to retain protein 
stability266. SGF and SIF are based on a fasted state of the stomach. Fed state versions of SGF 
and SIF are also made available, however, the pH of the gastric fed state is 5 compared to 1.6 in 
the fasted state. We chose to do all in vitro simulated fluid studies in the harsher fasted state 
conditions to test the durability of our NPs and oral delivery vehicle. Figure 3.2 shows that eGFP 
NPs lose 30% of its fluorescence in SIF and 100% of its fluorescence in SGF. pH appears to be 
the main driving force behind loss of eGFP fluorescence since was no time dependence as would 
be expected with enzymatic degradation of eGFP. Loss of fluorescence is dependent on the pH 
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to 7.4. Below pH 3, the fluorescence cannot be recovered and there seems to be an irreversible 
loss of more than 50% of eGFP fluorescence. Soluble eGFP has been reported to completely lose 
fluorescence at pH 2, however, it is able to undergo complete fluorescence recovery when 
buffered back to pH 8273. As the limit for eGFP NPs to fully recover is pH 3, it appears that NPs 
lose some ability to recover pH-induced fluorescence loss compared with soluble protein. The 
pH-induced loss of eGFP fluorescence is due to pronation of tyrosine-66 affecting the interaction 
with the chromophore within its b-can274. The inability of eGFP NPs to completely recover 
fluorescence suggests that the crosslinking may affect the ability of tyrosine-66 to reengage the 
chromophore. This is informative because it demonstrates the need for buffering capacity in an 
oral delivery vehicle. We have previously shown that AvrA NPs are active in the murine colon 
physiological environment51, so the harsh conditions found in the stomach would be the major 
limiting step in implementing an oral formulation. It is therefore necessary to design and 
encapsulate therapeutic NPs within an oral delivery vehicle that is capable of buffering against 








Figure 3.2: In Vitro eGFP NP Stability. A) eGFP NP stability in simulated intestinal and gastric 
fluids. B) eGFP NP fluorescence pH dependence and fluorescence pH recovery 
 
AvrA NPs were mixed with alginate and droplets were formed using a flow focusing 
microfluidic device (Figure 3.1). The droplet size was controlled by tuning the flow rates of the 
dispersed and continuous phase. Droplets were then crosslinked with calcium. A representative 
phase contrast and fluorescent image is seen in Figure 3.2 Alginate MPs crosslinked with 
calcium have an average size of 311 ± 41 µm and have a z-potential of -12.6 ± 1.9 mV in water 
(Figure 3.3). Alginate MPs have a tadpole morphology resulting from the uneven calcium 
gelation at the oil/water interface in the collection bath. This morphology has been reported 
before with alginate microparticles275. Alginate MPs had an eGFP NP encapsulation efficiency 
of 24.0 ± 4.4% with most of the NPs lost occurring during crosslinking. The collection bath 
contained 81.6 ± 9.5% of the initial eGFP NPs.  
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Figure 3.3: Phase contrast images of alginate only microparticles (left). Corresponding green 
fluorescence image (right). Scale bar = 200 µm 
 
 






3.3.2 Alginate/chitosan MPs protect and release eGFP NPs in simulated fluids 
In an effort to improve the encapsulation efficiency, chitosan was added into the 
collection bath with calcium. eGFP NPs were encapsulated within alginate MPs, coated with 




physiological pH to measure MP fluorescence retention. We found that without the chitosan, 
alginate MPs did not retain any eGFP NP fluorescence, as seen in Figure 3A. This could be due 
to a combination of drug leakage and irreversible pH denaturation of the proteins in the NPs. 
Alginate MPs have a reported pore size distribution between 5 - 200 nm throughout the entire 
core with smaller pore size distribution near the surface of the MP218. As a pH-responsive 
polymer, alginate MPs also shrink at low pH and swell at physiological pH. The NPs are ~275 
nm, suggesting that it is unlikely that they would diffuse out of the alginate MP during the SGF 
incubation. Therefore, the majority of the fluorescence loss seen in Figure 3.5 is likely due to the 
pH denaturation rather than eGFP NP leakage. In either case, the inability of the alginate MPs to 






Figure 3.5: In Vitro Gastric Protection of eGFP NPs in MPs. A) Effect of chitosan coating on 
eGFP NPs in MPs following gastric incubation. B) Representative phase contrast image of eGFP 
NPs in MPs and C) fluorescence image of eGFP NPs in MPs. Scale bar = 200 µm 
 
Chitosan coatings on alginate hydrogels have been studied for their ability to make a 
polyelectrolyte complex (PEC) capable of reducing drug leakage219, 276, 277. Chitosan can also 
provide buffering capacity in the gastric environment through pronating of its amine groups278, 







































































pronation of carboxyl groups, which have a pKa of ~3.4, though to a lesser extent than chitosan 
due to the differences in pKa between the amine and carboxyl groups. Coating chitosan onto 
alginate MPs after calcium crosslinking (“two-step” process) did not improve protection of eGFP 
fluorescence in SGF better than alginate only MPs, as seen in Figure 3.5. The two-step coating 
was ineffective in producing a sufficient chitosan layer and provided no additional SGF 
protection. We speculate that the failure of the two-step process to make sufficient protective 
chitosan coating is due to the loss of the electrostatic driving force. The G residues on the 
alginate chain were already saturated with calcium, which is an ionic crosslinker that allows the 
alginate to gel. After calcium crosslinking, the alginate beads are submerged in a pH 5.5 chitosan 
solution. The pH of the solution is near the pKa of the chitosan to prevent unwanted protein 
hydrolysis and denaturation, whichmeans that a lower percentage of the chitosan amine groups 
are protonated. This coupled with the calcium saturated carboxylate groups on alginate leads to 
little to no chitosan coating on the MPs.  
A 1-step simultaneous chitosan coating and calcium crosslinking process leads to 
competition of calcium and chitosan for alginate binding sites, and increases the amount of 
chitosan on alginate MPs. Increasing amounts of chitosan in the collection bath, with constant 
calcium concentration, leads to higher retention of eGFP fluorescence in SGF as seen in Figure 
3.5. Figure 3.5 shows that higher concentrations of chitosan in the collection bath confers 
increasing gastric protection of eGFP fluorescence. Increasing the chitosan concentration lead to 
overall higher levels of gastric protection consistent with other reports208, 210, 211 but can also 
hinder NP release211. 1-step 0.5% chitosan coating was chosen and used for all future 




Alginate/chitosan MPs have an average size of 335 ± 50 µm determined by phase 
contrast microscopy. A representative phase contrast and fluorescent image is seen in Figure 3.5. 
Particles are more spherical compared with alginate only MPs and have an acorn morphology 
more than tadpole morphology. This “acorn” morphology is owed to the uneven coating and 
crosslinking that occurs when alginate droplets enter the collection bath interface. 
Alginate/chitosan MPs had an eGFP NP encapsulation efficiency of 59.9 ± 1.1% and only 37.1 ± 
10.0% of the initial eGFP NPs were found in the collection bath. The addition of chitosan in the 
collection bath increased the eGFP NP encapsulation efficiency by approximately 35%. When 
chitosan is introduced in the collection bath, it acts as a crosslinker in addition to the calcium and 
increases the overall rate of crosslinking and, therefore, retention of the NPs.  
The alginate/chitosan MPs z-potential was measured to ensure that a chitosan coating 
was achieved. Alginate/chitosan MPs have a z-potential of -12.6 ± 1.9 mV in water (Figure 3.4). 
The switch in sign from negative to positive when chitosan was introduced was predicted given 
the complementary electrostatic properties of the two polysaccharides. The chitosan coated 
alginate MPs encapsulating eGFP NPs or AvrA NPs were analyzed with confocal microscopy to 
support that the chitosan coating procedure was successful. eGFP NPs were mixed with alginate 
and monomeric red fluorescent protein (mRFP) NPs were mixed with chitosan prior to NPs in 
MPs fabrication. A confocal cross section (Figure 3.6) indicates that green alginate MPs have a 
red chitosan coating around them. We estimate the chitosan coating is approximately 30 µm 





Figure 3.6: Confocal slice of alginate/chitosan microparticle. eGFP NPs were loaded into the 
alginate and formed the alginate core. mRFP NPs were loaded in the chitosan and make up the 
chitosan coating. Scale bar = 200 µm. 
 
Table 3.1 Size and ζ–potential of NPs and Microparticles 
 
One-step 0.5% chitosan coated alginate MPs were tested for release of functional eGFP 
NP cargo after simulated gastric incubation. Figure 3.7 shows fluorescence of eGFP NPs 




NPs in MP exhibited fast burst release in both cases. This shows that MPs are able to both 
protect eGFP NPs in SGF and subsequently release them in SIF. Approximately 70% of 
encapsulated NPs were released.  
To ensure that MP released NPs were still able to be taken up by cells, they were 
incubated with HeLa cells. In Figure 3.7, MP released eGFP NPs achieve an uptake efficiency of 
~65% normalized to cells that internalized eGFP NPs that were never encapsulated in MPs. This 






Figure 3.7: In Vitro release of eGFP NPs from MPs. A) eGFP NPs release kinetics from 1-step 
0.5% chitosan MPs in SIF with and without prior incubation in SGF, normalized to eGFP NPs in 
MPs that have not undergone simulated fluid incubated. B) MP released eGFP NPs uptake in 
HeLa cells normalized to an fluorescent equivalent amount of eGFP NPs that have not been 
encapsulated. C) MP released eGFP NPs associate with ex vivo section of mouse small intestine 
(scale bar = 100 µm). Actin is stained in red, nuclei in blue, and green signal is native eGFP 
fluorescence. 
 
To evaluate if NPs released from MPs can penetrate mucus and associate with the 
underlying cells, they were incubated with ex vivo sections of small intestine from mice. 
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Confocal images in Figure 3.7 show active (fluorescent) protein associated with cells found in 
the villi and crypt regions. We cannot conclude there was active uptake as the cells in ex vivo 
sections may not have been viable during the entire incubation period. However, the SIG-SIF 
MP released eGFP NPs were able to penetrate the adherent mucus layer to reach the cells 
underneath and motivates in vivo assessment. Altogether, these results show that 
alginate/chitosan MPs protect eGFP NPs in the simulated gastric environment and subsequently 




3.3.3 Oral delivery of NPs in MPs protect and release eGFP NPs in healthy mice 
After establishing the protection and release of eGFP NPs from alginate/chitosan MPs in 
vitro, we assessed performance in an in vivo oral delivery model. Healthy mice were gavaged 
with empty MPs, unprotected eGFP NPs, and eGFP NPs in MPs after overnight fasting. After 4 
hours, mice were sacrificed and the duodenum, jejunum, and colon were harvested, 
immunostained for eGFP, and imaged by confocal microscopy. Figure 3.8 shows a table of 
representative images of crypt cells and villi in the duodenum and jejunum of mice. No eGFP 
was detected in mice gavaged with empty MPs. eGFP was detected in the duodenum and 
jejunum of mice that were gavaged with both unprotected eGFP NPs and eGFP NPs in MP. The 
first third of the intestine, the duodenum, immediately follows the stomach and receives bile, 
stomach acid, and digestive enzymes still working to break up the contents of the stomach. The 
jejunum constitutes the largest portion of small intestine and has primary uptake function. 
Expectedly, we observed more eGFP in the jejunum than the duodenum, especially in the crypt 






Figure 3.8: Oral delivery of eGFP NPs in MPs gavaged to healthy fasted mice. Representative 
confocal slices of from 20 µm sections of different sections of the intestine. Villi are long 
fingerlike projections that sample the contents of the lumen. The lamina propria, which is located 
within the villi, is where immune cells residue. Crypts are regions farthest from the lumen 
inhabited by stem cells that differentiate into enterocytes, goblet cells, Paneth cells, and 
endocrine cells. Nuclei are stained with Hoechst in blue, b-catenin is stained with anti-b-catenin 
in red, and eGFP is stained with anti-eGFP in green. Scale bar = 20 µm. 
 
 
Detecting eGFP NPs in the crypts implies that eGFP NPs are released from MP and are 
able to penetrate the mucus to reach cells furthest away from the lumen of the intestine. Our NPs 
were designed to penetrate the mucus and enhance cellular internalization. The slight negative z-
potential of the NPs coupled with their size allows NPs to repel the mucin fibers and diffuse 










with cells within the lamina propria was promising because it suggests that eGFP NPs are 
penetrating the epithelial layer of the villi. Immune cells are known to residue within the lamina 
propria280 however, from these images the specific cell types cannot be identified without 
staining of specific immune cell surface markers. Of particular interest was the difference in 
positive detection of eGFP in the colon of mice between unprotected eGFP NPs and eGFP NPs 
in MPs as seen in Figure 6A, B. We observed more eGFP in the colons of mice gavaged with 
eGFP NPs in MPs compared with unprotected eGFP NPs. Unprotected eGFP NPs were unable to 
fully transverse the small intestine to reach the colon and the majority of the uptake was limited 
to the jejunum. eGFP NPs in MPs were able to access the entire length of the gastrointestinal 





Figure 3.9: Oral delivery of eGFP NPs in MPs (4 mg of MPs, 200 ug of NPs)  gavaged to 
healthy fasted mice (n=5). A) Representative 2D maximum projections taken from the colon. B) 
Matlab analysis of eGFP signal in 2D maximum projections. Baseline green fluorescence was 
determined from control mice gavaged with empty MPs. A positive score indicates that the green 
fluorescence was significantly different from the control. A negative score indicates not 
significant different from the control. P < 0.05 
 
It should be noted that a polyclonal anti-eGFP primary antibody and fluorescently 
conjugated secondary antibody were used to detect eGFP in the intestine and colon. Oral 
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gavaged eGFP NPs spread over the entire length of the gastrointestinal tract and therefore 
concentrations in specific sections were too low to detect eGFP by its native fluorescence, which 
necessitated immunohistochemistry to amplify the eGFP signal. Another caveat is the gastric pH 
difference between mice281 and humans282. Mice gastric pH reaches a low of 3 while in humans 
gastric pH can be as low as 1. This difference means that additional optimization could be 
required to achieve similar delivery in humans. Also in IBD patients, the pH in the small 
intestine and colon is slightly lower than in normal healthy individuals202. This could lead to 
reduced or slower release of NPs from the MPs. 
 
 
3.3.4 AvrA NPs in MPs reduce inflammation in murine DSS-induced colitis 
Inducing inflammation in the small intestine of mice generally requires transgenic 
knockout mice models or adoptive T-cell transfer and even in those cases, inflammation is 
limited to the ileum259. More common models are chemically induced colitis that offer a 
straightforward method to study gut inflammation283. Detection of eGFP in the colon of healthy 
mice was a motivator to pursue preclinical applications of a therapeutic for IBD. AvrA NPs were 
loaded into alginate/chitosan MPs and gavaged daily into mice for 5 days. After pretreatment, 
3% DSS (36000 – 50000 MW) was added to the drinking water and the mice were allowed to 
drink ad libitum for an additional 10 days while continuing to receive daily AvrA gavages. DSS 
is a sulfated polysaccharide that is toxic to intestinal epithelial cells of the basal crypt283, 284. It 
induces severe inflammation restricted to the colon perpetuated by an innate immune response. 
After DSS treatment, mice were sacrificed and the colons were harvested and preserved as swiss 
rolls. Representative images are shown in Figure 3.10. Evidence of eGFP was observed in the 




and eGFP NPs in MPs but not the other treatment groups. This suggests that AvrA NPs are still 
able to be released from MPs and penetrate the mucus in an inflammatory environment to reach 
the underlying cells, similar to the results in healthy mice in Figure 3.8.  
  
Figure 3.10: Oral Delivery of AvrA NPs in MPs uptake in inflamed mucosa. Representative 
confocal images of a 10 µm paraffin embedded colonic swiss roll from a mouse treated with 
empty MPs, eGFP NPs in MPs, and AvrA NPs in MPs (4 mg of MPs, 200 ug of NPs). Nucleus is 
stained in blue, b-catenin is stained in red, and eGFP stained in green.  Scale bar = 50 µm. 
 
Weight change was recorded as a macroscopic clinical indicator of colitis symptoms285. 
The daily weight change percentage as compared to pretreatment for the course of this 
experiment is seen in Figure 3.11. There was no significant difference between any of the 
experimental groups (n = 5) during the pretreatment phase, suggesting no major negative effect 
of any treatment group. After DSS was introduced, all experimental groups exhibited a minor 
increase in weight gain and then a steady decrease until the mice were sacrificed. Mice receiving 
4 mg of AvrA NPs in MPs (containing 200 µg of AvrA NP with 16 µg of AvrA) had 
significantly less weight loss than mice receiving no treatment. All other DSS treatment groups 
(AvrA NPs, Empty MPs, and eGFP NPs in MPs) exhibited the same amount of weight loss as 
untreated DSS mice. Figure 8B shows disease activity index (DAI) that was assessed after DSS 




was introduced to evaluate the clinical progression of colitis. DAI is a combined score of weight 
loss compared to pretreatment weight, stool consistency, and fecal occult blood. DSS mice 
receiving AvrA NPs in MPs showed a significant reduction in DAI during the last 4 days of 
treatment compared with the DSS untreated group. All other treatment groups show no 
significant reduction compared with the untreated group. 
  
Figure 3.11: Oral Delivery of AvrA NPs in MPs in murine DSS-induced colitis improve clinical 
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in MPs (200 µg of AvrA NP, 16 µg of AvrA)). 5 days of pretreatment followed by 10 days of co-
treatment with DSS. * p < 0.05 compared to DSS group. B) Clinical disease activity index 
scoring of 5 mice per indicated condition after DSS was introduced. * p < 0.05 compared with 
DSS group. C) Intracellular myeloperoxidase activity of caecum harvested from mice. * p < 0.05 
compared with DSS group. 
 
 
We measured intracellular caecal myeloperoxidase (MPO) activity as a proxy for 
neutrophil infiltration286, a downstream effect of inflammation. The results are seen in Figure 
3.11. AvrA NPs in MPs was the only treatment group that significantly reduced caecal MPO 
activity in DSS-induced colitis mice. This reduction in MPO activity supports the reduction in 





Figure 3.12: Oral Delivery of AvrA NPs in MPs in murine DSS-induced colitis improve 
histological scores. A) Representative histological sections of 10 µm paraffin embedded swiss 
rolls under 40x magnification. B) Histological scoring of 5 mice per condition. * p < 0.05 
compared to DSS group. 
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Histology was performed on 10 µm paraffin slices taken from the colonic swiss rolls 
subjected to hematoxylin and eosin staining (H&E). Representative images are seen in Figure 
3.12. We observe loss of crypt architecture, inflammatory cell infiltration, and muscle thickening 
in experimental groups receiving DSS. However, in mice gavaged with AvrA NPs in MPs, we 
see a reduction in severity of these histological markers, which is quantified as crypt damage, 
polymorphonuclear (PMN) infiltration under high-power field (HPF), depth of injury, and 
severity of inflammation, in Figure 3.12. Low magnification whole swiss roll colonic sections 
stained with H&E are in Figure 3.13. These images give a sense of the overall severity of the 
colitis between the different experimental groups. Combined, these results suggest that AvrA 
NPs are able to reduce the downstream macroscopic effects of DSS-induced colitis when 
delivered in alginate/chitosan MPs. 
 
PBS PBS + DSS AvrA NPs + DSS




Figure 3.13: Representative histological sections of 10 µm paraffin embedded swiss rolls under 
4x magnification. 
 
We have previously shown51 that two doses of 10 µg of AvrA NPs (900 ng of AvrA) 
administered transrectally significantly reduced DSS-induced colitis and symptoms. The current 
treatment plan requires daily doses of 4 mg of MPs, which contains 200 µg AvrA NPs (16 µg of 
AvrA in each dose), for 2 weeks. Based on the comparison of these dosing schemes, we estimate 
that alginate/chitosan MPs have colonic delivery efficiency of ~1%. This suggests that most of 
the NPs are being taken up much earlier in the gastrointestinal tract or they are irreversibly 
entrapped within the alginate and chitosan MPs. There is significant room to improve the colonic 
delivery efficiency of AvrA NPs. Others have reported the colon-homing abilities of therapeutic 
NPs within alginate/chitosan hydrogels285. This system does not use microparticles, but rather 
two separate gavages of first the alginate/chitosan mixture followed up the gelation solution 
containing their NPs. A straightforward method would be to provide an additional coating on our 
MPs with a biocompatible pH-sensitive polymer such as Eudragit ®223 that can tune the release 
of NPs from MPs in a desired pH environment. Although the AvrA NPs have low colonic 
delivery efficiency, they could prove to be effective in treating CD, which can manifest much 




AvrA is a bacterially derived enzyme capable of immunomodulation via intracellular 
activity. Previous work demonstrated that transrectal delivery of AvrA NPs was successful in 
reducing inflammation in murine colitis models. To implement AvrA NPs as a clinically viable 




capable of releasing AvrA NPs in the small intestine and colon. Alginate/chitosan MPs protected 
protein activity in SGF in vitro and reduced macroscopic symptoms in a murine DSS-induced 
colitis pre/co-treatment model. This platform could be expanded to use alginate/chitosan MPs to 
encapsulate and orally deliver other bacterial protein therapeutics, vaccines, or antibodies to the 







CHAPTER 4 : Carrier Proteins to Control Protein Nanoparticles Properties for Assessing 





NPs have been widely used to improve intracellular drug delivery287. In most cases, NPs 
are internalized by energy dependent endocytic processes. However NPs or their encapsulated 
drugs must escape endosomes to gain access to the cytosol prior to lysosomal degradation or 
endosome recycling288. This is a significant challenge for many NP systems and reduces the 
efficiency of cytosolic drug delivery, especially for macromolecules such as proteins.  
Soluble proteins typically cannot cross the cell membrane to reach the cytosol directly. 
Protein NPs offer a means to turn soluble protein into a colloidal drug carrier, capable of 
enhancing cellular uptake through active endocytic uptake mechanisms289 and altering 
biodistribution290. Protein properties and characteristics (size, charge, and hydrophobicity) affect 
the final protein NP structure and properties, which, in turn, affect cellular interactions and 
uptake. It is known that size, shape, surface charge, surface chemistry or functionality, 
hydrophobicity, and the absorbed protein corona all affect the ability of nanomaterials to be 
internalized and trafficked291.  For example, size and charge of NPs can regulate receptor-
mediated internalization. Size affects the binding capacity of NPs to receptors by modifying 
membrane wrapping kinetics292. Charge affects the adsorption of serum proteins and alters 
conformational charges affecting their accessibility to receptors (e.g. scavenger receptors)293. 
Cationic NPs have increased cell binding over anionic NPs due to the electrostatic interactions 
with the negatively charged cell surface. While these cationic particles may promote cell 
binding, they also promote formation of a protein corona that marks them for cell clearance293. 




the protein mediate anionic NP binding to native receptors on the cell293. NP surface properties 
can also promote affinity toward specific receptor-mediated endocytosis pathways177, 295, 296 and 
allows for targeting preferred endocytic routes. Cationic NPs have been reported to increase 
internalization by clathrin-mediated endocytosis296, but are guided toward degradation168. 
Anionic NPs have decreased internalization rates and are guided toward caveolae-mediated 
endocytosis, however, are not marked for degradation168. The importance of serum protein 
corona formation on NPs has been revealed as NPs become closer to clinical implementation. 
However, most of the NP used to study corona are limited to solid inorganic materials such as 
gold or dense polymeric NPs such as polystyrene.  
Protein NPs are made of proteins and present an inherent pseudo-corona on their surface. 
Properly folded proteins minimize their free energy and orient their hydrophobic domains in 
their cores. Unfolding and denaturing proteins allows these hydrophobic regions to interact and 
increase the propensity to aggregate. It is unknown how what the conformation of proteins on the 
protein NP surfaces are, however, due to the method of synthesize, it is likely that some 
unfolding occurs. How then do the folded serum proteins interact with protein NP surfaces and 
how this differs from traditional NP carriers is one of the main question we sought to explore in 
this chapter. Therefore, studying protein NPs with different surface properties can elucidate these 
differences. Little is known about how the properties of the carrier protein translate to protein NP 
characteristics, which ultimately affect the cellular uptake mechanism of the NP. Furthermore, 
the increasing realization that proteins in various physiological fluids, such as blood, interact 
with NPs and can modify their size, surface charge, surface composition, and functionality. This 
chapter aims to understand how protein NP properties can alter protein corona formation which 




to produce protein NPs with different properties and how these different protein NP properties 
affect the composition of the protein corona. The future goal is to influence cellular interactions 
to increase cytosolic delivery. 
 
 
4.2 Experimental Methods 
 
4.2.1 Protein nanoparticle synthesis through desolvation 
Protein NPs were prepared by desolvation technique as previously described51 with minor 
modifications. Bovine serum albumin (BSA) (Sigma-Aldrich) was dissolved in MilliQ water to a 
concentration of 200 mg/mL. 3,3’-dithiobis(sulfosuccinimidyl propionate) (DTSSP; Pierce) was 
dissolved in MilliQ water to 15 mg/mL immediately prior to use. The bottoms of 1.5 mL LoBind 
microcentrifuge tubes (Eppendorf) were cut and 100 µL of BSA solution was transferred in with 
a flea stir bar (VWR). Tubes were placed upside down and stirred at 600 rpm in the cold room 
(4ºC) for 10 minutes. 200 µL of pre-chilled 4°C ethanol (Decon Labs) was added at 1 mL/min to 
desolvate the BSA. 128 µL of DTSSP solution was added immediately after ethanol desolvation. 
The solution was stirred for an additional 90 minutes in the cold room. Afterwards, the solution 
was transferred to another centrifuge tube and centrifuged at 7,000 x g for 5 minutes. The 
supernatant was discarded and the pellet was resuspended in 500 µL of sterile PBS and sonicated 
on ice for 1 s every 3 s at 65% amplitude for 1 minute. The solution was then centrifuged at 5 
minutes at 500 x g. The supernatant was collected, pellet discarded, and subjected to additional 
centrifugation for 5 minutes at 500 x g. The supernatant was then collected, pellet discarded, and 




discarded, and the pellet was resuspended in 500 µL of sterile PBS and sonicated on ice for 1 s 
every 3 s at 65% amplitude for 1 minute to make the final BSA NP product. 
OVA (Sigma-Aldrich) was dissolved in PBS to a concentration of 6.2 mg/mL. DTSSP 
was dissolved in PBS to 10 mg/mL immediately prior to use. 100 µL of the OVA solution was 
transfered to a 0.5 dram glass vial with a flea stir bar and stirred at 650 rpm on a stir plate. 400 
µL of 100% ethanol was added at 1 mL/min. Afterward, the solution was transferred to a 1.5 mL 
LoBind microcentrifuge tube at centrifuged for 5 minutes at 7,000 x g. The supernatant was 
discarded and the pellet was resuspended in 475 µL of sterile PBS and sonicated on ice for 1 s 
every 3 s at 65% amplitude for 1 minute. 25 µL of the DTSSP solution and a flea stir bar were 
added, the microcentrifuge tube inverted and stirred at 650 rpm on a stir plate at room 
temperature. After 60 minutes, stir bar was removed and the solution was centrifuged for 30 
minutes at 18,000 x g. The supernatant was discarded and the pellet was resuspended in sterile 
PBS and sonicated on ice for 1 s every 3 s at 65% amplitude for 1 minute to obtain the final 
OVA NP product. 
Avidin (e-Proteins) was dissolved in imidazole elution buffer (250 mM imidazole, 300 
mM NaCl, 50 mM NaH2PO4; pH 8) to a concentration of 10 mg/mL. DTSSP was dissolved in 
MilliQ water to a concentration of 4 mg/mL immediately prior to use. 100 µL of the avidin 
solution was transferred to a 0.5 dram glass vial with a flea stir bar and stirred at 650 rpm. 400 
µL of acetone (VWR) was added at 1 mL/min. 64 µL of the DTSSP solution was added and the 
solution spun for an additional 90 minutes at room temperature. Afterwards, the solution was 
transferred to a 1.5 mL LoBind centrifuge tube and centrifuged for 5 minutes at 7,000 x g. The 
supernatant was discarded and the pellet was resuspended in 500 µL of sterile PBS and sonicated 






4.2.2 Size, zeta-potential, and concentration measurements of nanoparticles 
Average NP size was characterized using Zetasizer Nano ZS90 (Malvern Instruments 
Ltd.) with a minimum of three batches of each NP type with three replicates of 10 measurements 
using the following settings: proteins setting for NP detection and manufacturer PBS settings as 
the dispersion medium. NP z-potential was determined by measuring the electrophoretic 
mobility of the NPs in PBS using the same instrument. The NP protein concentration was 
determined using a BCA assay (Pierce) following the manufacturer’s protocol.  
 
4.2.3 Protein nanoparticle hydrophobicity measurements determined by ANS 
8 mM of 1-anilinonaphthalene-8-sulfonic acid (ANS; TCI America) was prepared in 0.1 
M phosphate buffer (81 mL of 0.2 M dibasic sodium phosphate, 19 mL of 0.2 M monobasic 
sodium phosphate, and 100 mL of distilled water) as a stock solution immediately prior to use. 2 
mL aliquots of BSA, OVA, and avidin as NPs and soluble protein were prepared at 100 μg/mL, 
50 μg/mL, 25 μg/mL, 10 μg/mL, and 5 μg/mL in 0.1 M phosphate buffer. 10 µL of the stock 
ANS solution was added to each protein aliquot along with a 0.1 M phosphate blank solution. 
These aliquots were vortexed for 10 seconds and the fluorescence intensity was measured in a 
Bio-Tek Synergy 2 plate reader using 390 nm as the excitation and 470 nm for the emission. The 
relative fluorescence intensity (RFI) was calculated as the difference between the fluorescence 
values of the protein solutions compared to the blank. The RFI values of each sample was plotted 
against the protein concentration and the slope of the line was determined by linear regression 






4.2.4 FITC conjugation 
FITC conjugation of serum allows fluorescent detection of serum proteins separate from 
protein NPs during SDS-PAGE analysis. Fluorescein isothiocyanate (FITC; Sigma-Aldrich) was 
dissolved in dimethyl sulfoxide (DMSO; BDH) to 0.2 M. 2.5 mL FITC was mixed with an equal 
volume of 0.1 M sodium carbonate-bicarbonate buffer at pH 9 (10 mL 0.1 M sodium carbonate 
and 90 mL of 0.1 M sodium bicarbonate). The buffered FITC solution was mixed with an equal 
volume of fetal bovine serum (Seradigm Premium Grade; VWR) and rotated for 2 hrs at room 
temperature. Afterwards, the mixture was transferred into a 3.5 kDa MWCO membrane 
(Spectrum Laboratories Inc.) and dialyzed into PBS.  
FITC conjugation of nanoparticles allows fluorescent detection of NPs uptake in cells. 
The buffered FITC solution was mixed with equal volumes of BSA, OVA, or avidin NPs with a 
concentration of 2 mg/mL and rotated at room temperature for 2 hrs at room temperature. 
Afterwards, the mixtures were transferred into a 10 kDa MWCO Slide-A-Lyzer MINI dialysis 
device (ThermoFisher Scientific) and dialyzed into PBS. 
 
 
4.2.5 Protein corona preparation using FITC-conjugated serum 
1 mg of BSA, OVA, and avidin NPs, and polystyrene beads (polybead carboxylate 0.20 
µm microspheres; Polysciences) were incubated with 1 mL of FITC-conjugated serum at 37°C 
for 1 hr under end over end rotation. Afterwards, the NP-serum mixtures were washed by 
centrifugation at 7,500 x g for 10 minutes at 4°C. The supernatant was collected and stored for 
future analysis. The pellet was resuspended via pipetting with 1 mL of sterile PBS. A total of 5 
washes were performed to remove the soft corona. After the wash steps, the pellet was 







4.2.6 Gel analysis of protein corona 
10 μL of NPs with hard corona obtained in the previous section were heated with 30 μL 
of sodium dodecyl (lauryl) sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) loading 
buffer (50 mM Tris-Cl, pH 6.8, 2% SDS, 100 mM DTT, 0.1% bromophenol blue, 10% glycerol) 
for 15 minutes at 95°C and 20 μL were loaded into a 12% SDS polyacrylamide gel. After SDS-
PAGE, the gels were analyzed for FITC fluorescence using a Gel Dox XR+ Gel Documentation 
System (Bio-Rad). After FITC imaging, the gels were stained with Coomassie.  
 
 
4.2.7 Confocal microscopy for qualitative assessment of nanoparticle uptake 
HeLa cells were cultured in (DMEM), supplemented with 10% (v/v) (FBS). Media was 
also supplemented with 1% penicillin/streptomycin, and cells were incubated in a 5% CO2 
humidified air atmosphere. HeLa cells were plated at a density of 10,000 cells per well in an 8-
well chamber slide system overnight. After attachment, cells were then incubated with 500 
μg/mL of FITC-conjugated BSA, OVA, and avidin NPs that were preincubated in media for 1 hr 
at 37°C. NPs were incubated with cells for 12 hrs. Afterwards, cells were washed twice with ice 
cold PBS and fixed with 3.7% paraformaldehyde for 15 minutes at room temperature. Cells were 
then permeabilized with 1% Triton X-100 in PBS for 15 minutes at room temperature. Actin was 
stained with 0.33 µM phalloidin-tetramethylrhodamine B isothiocyanate (phalloidin-TRITC; 
Sigma-Aldrich) for 15 minutes at room temperature and the nucleus was stained with 0.2 μM 
Hoechst 33342 for 15 minutes at room temperature. Cells were washed three times with PBS in 




media and samples were sealed with a coverslip and nail polish. Images were taken on Zeiss 
LSM 700 confocal microscope and analyzed with Zen Black software (Zeiss). 
 
 
4.2.8 Nanoparticle cytotoxicity determined by MTT 
10,000 HeLa were plated in a 96 well plate overnight. After attachment, media was 
replaced with BSA, OVA, and avidin NPs that were preincubated with media for 1 hr at 37°C. 
Different concentrations of NPs incubated with cells. After 6 hrs of NP incubation, media was 
replaced with 100 μl of fresh media and 10 μl of MTT solution. Cells were incubated with MTT 
reagent for an addition 4 hrs. 200 μl of DMSO was then added to each well and wells were 
mixed vigorously to ensure cells were lysed. Absorbance was measured using a Biotek Synergy 
2 Microplate reader at 570 nm and background absorbance 630 nm was subtracted. Cell viability 





4.3 Results and Discussion 
 
 
4.3.1 Synthesis and characterization of BSA, OVA, and avidin nanoparticles 
To elucidate the role of carrier protein in influencing protein NP properties after 
desolvation, model cationic, anionic, hydrophobic, and hydrophilic carrier proteins were used. 
Avidin is a highly basic 66 kDa tetrameric protein with a pI = 10.1 that is normally studied for its 
strong binding interaction with biotin.  Avidin is rich in arginine (eight/subunit) and lysine 




serum albumin (BSA) is an acidic 66.5 kDa protein with a pI = 4.7 that is used in many 
biological applications for its relative bio-inertness and low cost. BSA was selected for its 
anionic and hydrophobic properties. Ovalbumin (OVA) is a 45 kDa protein with a pI = 5.2 that is 
commonly used in immunological studies. It possesses hydrophilic properties298 in contrast with 
hydrophobic BSA, though their pI values are similar. These model proteins were chosen for their 
varying range in surface charge and hydrophobicity and because they are well characterized and 
easily obtainable.  
Solutions of soluble BSA, OVA, and avidin were desolvated to form nanoclusters and 
stabilized with a cleavable disulfide bond crosslinker, DTSSP, to make BSA, OVA, and avidin 
NPs. The desolvation method of producing protein NPs is described earlier in this thesis. Size 
was the main criteria used when optimizing protocols to synthesize NPs. It was necessary to 
create protein NPs of similar size to control for size-dependent effects of protein corona 
formation.  Studies have shown that the larger the NP, the more surface area is available for 
corona adsorption and size influences the conformation of these serum proteins179. NPs with a 
size between 250 – 290 nm were obtained. A summary of the model proteins, their studied 






Figure 4.1: Model carrier proteins, their crystal structures obtained from literature, their 
characteristics, and corresponding DLS plots of NPs made via desolvation. 
 
 The surface charge of NPs is a commonly studied property that can greatly affect protein 
corona composition and cellular internalization. Cationic materials have the potential to 
electrostatically bind negatively charged cellular membranes and have the potential to alter the 
conformation of corona proteins leading affect what cellular receptors the corona target293. The 
zeta potential of NPs made from avidin, the model cationic protein, and BSA, the model anionic 
protein were measured and the results are seen below in Figure 4.2. 
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Figure 4.2: The zeta potential of BSA and avidin NPs and soluble proteins. 
 
 
 BSA NPs have a zeta potential of around -15 mV in PBS whereas avidin NPs have a zeta 
potential of around -2 mV in PBS. Avidin NPs do not appear to be as cationic as expected. It is 
possibly due to the dispersion media used as when BSA and avidin NPs and soluble proteins 
were tested in 10 mM HEPES buffer, avidin has a positive zeta potential, whereas BSA retained 
a negative value (data not shown). The salts in the media form an electric double layer around 
the NP. The inner layer is comprised of ions with opposite charge called the Stern layer. Beyond 
this layer, there is a diffuse layer of ions that is dynamic. Zeta potential measures the interface 
between the diffuse layer with bulk dispersant called the slipping plane during electrophoresis299. 
The reduced ionic strength in 10 mM HEPES means that a smaller electric double layer is 
present allow a more accurate reading of avidin’s surface charge. The zeta potentials in PBS are 
reported here as it was the more physiological relevant media. Though the zeta potential is not 
positive for avidin, there is a large difference in zeta potential between BSA and avidin NPs 






























 Hydrophobicity is another commonly studied property of NPs that is known to contribute 
to protein corona composition and cellular internalization by affecting the amount of serum 
proteins that bind the surface300. Hydrophilic NPs achieved through PEG conjugation have been 
used to extend circulation times by blocking adsorption of certain serum proteins to the surface 
to decrease cellular interactions183. To measure NP hydrophobicity, ANS, a hydrophobic 
fluorescent dye was used301. ANS is hardly fluorescent in aqueous environments but becomes 
highly fluorescent when bound to a solid surface. NPs of BSA, the model hydrophobic protein, 
and OVA, the model hydrophilic proteins and their soluble forms were incubated with ANS to 
determine hydrophobicity and the results are seen in Figure 4.3. ANS is only capable of 
measuring the relative the hydrophobicities between samples. Figure 4.3 shows a large difference 
in hydrophobicities between BSA and OVA as both NPs and soluble protein in agreement with 
other reported literature values298. 
 
 







































 It appears that OVA and BSA exhibit similar zeta potentials, however, vastly different 
hydrophilicities, whereas OVA and avidin exhibit similar hydrophobicities and vastly different 
zeta potentials. Overall, protein NPs made from different carrier proteins were synthesized and 
the NP properties were characterized. NPs desolvated from model carrier proteins exhibit similar 
properties to carrier proteins in their soluble form. It is concluded that carrier proteins govern 
protein NP properties after desolvation. These NPs can be used as tools to study the protein 
corona that forms when NPs are incubated with serum. 
 
4.3.2 Protein corona formation and analysis on nanoparticles 
A common method of qualitatively analyzing the protein corona is using SDS-PAGE178, 
302. The hard corona on inorganic or polymeric NPs separates from the NP when heated in 
reducing loading buffer and when the mixture is loaded into a gel, the NPs are unable to enter the 
gel due to their large size. This separation allows accurate analysis of the hard corona proteins. It 
should also be noted that the soft outer protein corona is much more difficult to analyze and 
remains a controversial topic. The reversible binding and dynamic nature of this outer layer 
makes it challenging to characterize and some literature questions even the existence of a soft 
corona302. Therefore, all future references to the corona refer to the hard corona unless otherwise 
specified. The difficulty with studying corona formation on protein NPs is that separating the 
corona from the protein NP results in NP breakup and allows the components of the protein NP 
to enter the gel as well. Since the amount of proteins that make up the protein NP core is much 
greater than the corona shell that forms around it, it is hard to distinguish the bands on SDS-




fluorescent detection of the proteins that are specifically associated with the corona303. The 
conjugation of serum can be seen in Figure 4.4 below. 
 
Figure 4.4: Serum and FITC-conjugated serum analyzed using SDS-PAGE. The coomassie 
signal is seen on the left and the FITC signal is seen on the right. 
 
 There is a strong signal resulting from the overloading of serum in the gel, which was 
done in order to visualize the lower abundancy serum proteins. This is seen in the massive band 
most likely from BSA as BSA is the majority component (~55%) in fetal bovine serum. It is 
important to note is that we are able to obtain FITC signal that allows us to distinguish serum 


















incubated with FITC-conjugated serum and the corona after washing was analyzed using gel 
electrophoresis. The results are seen below in Figure 4.5.  
 
Figure 4.5: PS, BSA, OVA, and avidin NPs and FITC-serum-incubated NPs analyzed in SDS-
PAGE imaged with coomassie blue and FITC fluorescence. 1 mg of NPs were used with 1 mL of 
FITC-serum and approximately 500 μg of NPs were loaded into each lane. 
 
PS NPs are well characterized as well as the corona that forms around them304. PS NP 
therefore can serve as a positive control and a point of comparison to protein NPs. It is difficult 
to discern between corona and protein NPs in the Coomassie stained gel. The corona is much 
clearer in the PS lanes. However, when fluorescently imaged, the contributions from serum are 
much easier to distinguish. In general, it appears that serum proteins adsorb onto PS NP in 
























































layer of BSA, OVA, or avidin proteins that could inhibit some binding. The strongest signal is 
the BSA band and in BSA NPs, there appears to be strong upper globulin bands as well. There is 
also a difference in FITC intensity and distribution of serum proteins adsorbed between BSA 
NPs and OVA/avidin NPs. The BSA band is the strongest on all three NPs though in much lower 
quantities on OVA/avidin NPs. Hydrophilic NPs are known to adsorb less protein than 
hydrophobic NPs300that contribute to reduction in overall intensity. There appears to be presence 
of lower molecular weight bands present on OVA NPs around 20 kDa – 50 kDa and smearing of 
upper bands between 65 kDa – 150 kDa that are not seen on BSA NPs. These lower molecular 
weight bands are possibly apolipoproteins and the upper smear are possibly complement proteins 
and plasminogen. This difference highlights the how different NP hydrophobicity can contribute 
to different adsorb serum compositions suggest a greater contribution from hydrophobicity than 
surface charge. A significantly amount of avidin NPs appear to have been lost during the 
washing steps making comparisons with avidin NPs difficult. In the future, the amount of NPs 
loaded into each lane must be normalized following wash steps to allow accurate comparisons 
between the NPs. 
Though we have developed a method to study corona composition on protein NPs, it 
primarily reveals qualitative differences. Further characterization must be done to determine the 
exact composition of the corona by mass spectrometry178. This will help determine if our protein 
NPs are being opsonized by immunoglobulins or complement proteins, which increase cellular 
endocytosis, or if apolipoproteins dominate, and could confer increased blood circulation 
times305. Probing the corona with specific antibodies by western blot can also provide some 
preliminary indications as to the NP biological identity. Isothermal calorimetry is another useful 




protein binding. Optimization of the injection and sample concentrations is critical along with the 
proper controls to distinguish between NP-NP interactions and serum-NP interactions. 
Ultimately, delivery of an intracellular therapeutic, such as AvrA, is necessary to determine the 
cytosolic delivery potential of these different protein NPs. Differences in the desolvation 
conditions will need to be reviewed to ensure equal loading of AvrA into the different protein 
NPs. Western blot analysis can confirm the loading. 
 
 
4.3.3 In vitro assessment of nanoparticle cellular interactions 
We examined whether the qualitative differences between the various NP coronas 
influenced cellular interactions. BSA, OVA, and avidin NPs were preincubated in media 
containing 10% fetal bovine serum and then incubated with HeLa cells to image cellular uptake. 
The images can be seen in Figure 4.6. 
 
Figure 4.6: Representative images of 500 μg/mL of FITC-BSA, FITC-OVA, and FITC-avidin 
NPs incubated with HeLa cells for a period of 12 hrs. Images shown are 2D maximum 
projections of confocal stacks.NPs are seen with the native green FITC signal, actin is stained in 
red, and the nucleus is stained in blue. Scale bar = 50 μm.  
 
 The confocal images seen in Figure 4.6 show the propensity of OVA and avidin NPs to 
aggregate on the surface of cells, whereas BSA NPs are dispersed and punctate, with less 




intensity. These results are interesting because BSA NPs are much more hydrophobic that OVA 
and avidin NPs, however, don’t appear to aggregate. OVA NPs appear to be stuck on top of 
cells, aggregating into large clusters. Avidin NPs appear to be having a cytotoxic effect on the 
cells, as seen by the lack of actin staining. To verify whether these protein NPs are cytotoxic, a 
MTT assay was performed with varying dosages of NPs and the results are seen in Figure 4.8. 
 
Figure 4.7: Dose-dependent cell viability of BSA, OVA, and avidin NPs preincubated with 
media determined by MTT assay. Viability was normalized to cells receiving an equal volume of 
PBS without NPs. 
 
 The OVA and avidin NPs concentrations used ranging from 200 μg/mL – 2 mg/mL in 
Figure 4.7 show a cytotoxic effect (viability < 80%). BSA NPs are extremely well tolerated. 
OVA and avidin appear to have a dose-dependent increase toxicity when the NP concentration 
increase above 100 μg/mL. This should inform future experiments with OVA and avidin NPs. 
We speculate that due to the hydrophilic nature of OVA and avidin NPs, the corona composition 
is contributing to the cytotoxicity and uptake. Cells appear to be inhibiting the uptake of OVA 






















similar clustering, however, negatively impact the actin structure. More work needs to be done to 
optimize the proper NP concentration used without compounding cytotoxic effects. Flow 
cytometry can also quantify the extent of NP uptake and using trypan blue with FITC-conjugated 
NPs can discern between internalized and attached NPs.  
 The goal of the work presented in this chapter use carrier proteins to control protein NPs 
properities and use these NPs to assess corona and cellular interactions. OVA NPs and avidin 
NPs have cytotoxic effects potentially due to their hydrophilic nature. Comparisons with PEG 
coated NPs can elucidate the cause of these cytotoxic effects. These NPs can be used in future 
studies to explore the uptake mechanisms and intracellular trafficking with endocytic pathway 
knockout experiments and imaging with lysosomal stains. Codesolvate these model carrier 
proteins with a therapeutic enzyme would provide a functional assay to measure the intracellular 
delivery and allow direct comparison between the different protein NPs and inform future work 




NPs continue to be developed for their ability to enhance intracellular delivery. The 
ultimate goal of these NPs is clinical implementation, however, once NPs are administrated in 
vivo, they come in contact the milieu of biological components in the blood that can alter NP 
properties. The protein corona that forms around NPs in vivo confers a biological identity and 
ultimately influences cellular internalization and trafficking. Studies on NP corona composition 




system exhibits different corona behavior and the impact this has on cellular uptake can inform 
future research with the goal of maximizing cytosolic delivery.  
Model cationic, anionic, hydrophobic, and hydrophilic proteins were investigated and 
shown to govern the NP properties after desolvation. These protein NPs were shown to display 
different amounts of serum adsorption, cellular uptake and cytotoxicity. Though much work 
needs to be done to understand how protein NP properties can be utilized to influence and 
maximize cytosolic delivery, some tools to explore this relationship ave been developed and 










The work presented in this thesis focuses on reengineering naturally-derived, 
evolutionarily optimized molecules as drug delivery vehicles and therapeutics. Pathogenic 
Salmonella has developed tools to promote its survival through the coevolution with the human 
immune system. We have identified AvrA, used by Salmonella, as an effector enzyme with 
therapeutic potential due to its ability to modulate key intracellular signaling pathways in 
eukaryotic cells and confer anti-inflammatory and anti-apoptotic effects. This enzyme is unique 
as its mechanism of action is not currently found in eukaryotic cells, highlighting how 
pathogenic bacteria can be a source for future therapies. Chronic inflammation in autoimmune 
diseases, such as inflammatory bowel disease, is a prime target that could benefit from treatment 
with AvrA. Current therapies rely on small molecule drugs that have poor side effects and 
emerging therapies focus on using antibodies to target extracellular components. Modulating 
intracellular components with the use of enzymes presents a new strategy to combat 
inflammatory bowel disease. Salmonella possesses a type three needle-like secretion system used 
to deliver AvrA which can penetrate the cell membrane, giving direct access to the cytosol. 
Utilizing AvrA absent of Salmonella requires an alternative delivery system.  
To address this challenge, we engineered a protein nanoparticle encapsulating AvrA 
capable of intracellular delivery. AvrA nanoparticles were characterized and evaluated for their 
potential to treat inflammatory bowel disease and a pH responsive oral delivery vehicle made 
from naturally derived polysaccharides, alginate and chitosan, was used to encapsulate AvrA 




nanoparticles to treat inflammation in vivo, nanoparticle delivery vehicles in general suffer from 
the common problem of endosomal entrapment that limits delivery efficiency. Therefore, we also 
studied the role of carrier proteins in influencing protein nanoparticle properties. These 
properties can influence the protein corona that around them when administrated in vivo and 
guide cellular interactions to maximize cytosolic delivery. 
 
The key findings from this thesis are: 
 
1. Protein nanoparticles are suitable alternative intracellular delivery vehicles to Salmonella 
type 3 secretion system. AvrA nanoparticles synthesized using a desolvation method 
were shown to enhance cellular internalization in vitro and maintain AvrA activity. 
Transrectal delivery of AvrA nanoparticles to two murine colitis models reduced clinical 
and histological scores of inflammation. AvrA nanoparticles demonstrate the potential of 
using protein nanoparticles as therapeutic delivery vehicles for the treatment of 
inflammation bowel disease. 
2. Alginate/chitosan microparticles that encapsulate protein nanoparticles can enable oral 
delivery of AvrA. pH responsive alginate hydrogels provide a gentle means of 
encapsulating protein nanoparticles for intestinal release. Coating alginate microparticles 
with chitosan increases protein nanoparticle encapsulation efficiency and improves 
retention of bioactive nanoparticles after gastric incubation. Oral gavage of AvrA 
nanoparticles encapsulated in alginate/chitosan microparticles reduced clinical and 




microparticles are effective oral delivery vehicles that provide gastric passage and 
intestinal release of bioactive protein nanoparticles. 
3. Carrier proteins govern protein nanoparticle properties after desolvation. Protein 
nanoparticles exhibit altered protein corona composition dependent on the carrier protein 
used. Serum protein adsorb in greater amounts on hydrophobic BSA nanoparticles 
skewed toward higher molecular weight bands. Hydrophilic OVA nanoparticles have 
fewer serum proteins adsorbed, however, display a wider range of bands. These 
differences can be potentially used to influence cellular interactions to increase cytosolic 
delivery. 
 
The findings of this thesis can inform others in the field of drug development of the 
remarkable ability of bacterial effector enzymes as therapeutic agents. These effector enzymes 
are evolutionary-optimized materials with specific immunomodulatory functions. Isolating the 
enzymatic domains from multiple effector proteins and potentially combining them into a single 
effector through protein engineering can tailor host stress response. Proteins are also excellent 
building blocks for drug delivery vehicles with favorable biodegradability profiles and 
modularity. Carrier proteins designed with specific physiochemical properties and structure 
through protein engineering can allow complete control of protein nanoparticles properties.  
Though we can design and engineer these protein nanoparticle delivery vehicles in lab, 
the question of what happens to these nanoparticles once administrated to human cannot be 
overstated. Understanding the biological response to these protein nanoparticles and how these 
nanoparticles interact with cells can inform future drug delivery vehicle specifications. The 




other nanoparticle carriers. Protein nanoparticles have an inherent pseudo-corona shell that can 
be altered through the individual protein building blocks it is made from. This system presents 
biologically recognizable domains on their surface that differs from polymeric and liposomal 
nanoparticles that can be utilized to control cellular interactions when systemically delivered. 
Delivery through the oral route is desirable. Using alginate and chitosan, two naturally-
derived polysaccharides, we provide a platform for gastric passage and intestinal release of 
protein nanoparticle therapeutics. Though our goal was the localized intestinal delivery of 
protein nanoparticles, systemic delivery of protein nanoparticles is another direction worth 
exploring. The therapeutics encapsulated within alginate/chitosan microparticles can also be 
expanded such as vaccines or probiotics. Each therapeutic will have unique oral delivery 
requirements that potentially necessitate additional coatings onto the alginate/chitosan 
microparticle.  
This work shows the potential for using naturally-derived products as drug delivery 
vehicles for intracellular protein therapeutics. The modularity and flexibility of these systems 
described provide potential for optimization and tailoring to toward specific delivery 
requirements. Future directions improving upon these existing system and other areas of 
investigation are described below. 
 
5.2 Future Directions 
 
5.2.1 Improving endosomal escape of intracellular proteins 
Endosomal escape is a common problem facing all nanoparticle delivery systems. Cell 
penetrating peptides are a common solution, however, their unclear mechanism and lack of 




entrapment. It is generally accepted that endocytosis is the major cellular uptake pathway for 
most cell penetrating peptides306 as opposed to previously reported direct penetration via energy-
independent pathways. This suggest that there could be specific cell receptors that recognize 
these peptides and therefore peptides can be designed to target specific cells and tissues307. Cell 
penetrating peptides were originally derived viral proteins that exhibit nuclear localization also 
suggesting that subcellular localization is also possible using peptides105. Specific amino acids 
combinations displaying organelle targeting were discussed in Chapter 1.3.2. Peptides can be 
designed with combinatory cell targeting and subcellular localization domains that would greatly 
enhance the specificity of protein therapeutics. Utilizing cell penetrating peptides on protein 
nanoparticle delivery vehicles can be accomplished by two strategies. These peptides can be 
cloned onto the terminuses of carrier protein and when desolvated will stochastically present 
onto the surface, though this would most of the peptides would be in the nanoparticle core. 
Peptides can be covalent conjugated to the surface of nanoparticles or can be adsorbed onto the 
surface. We observed increase serum adsorption onto the surface of hydrophobic protein 
nanoparticles in Chapter 4 and can leverage this finding to maximize the adsorption of peptides. 
Covalent conjugation or adsorption would allow a more complete coating and surface display 
compared to the cloning strategy. 
It has been reported that other bacterial effector enzymes, such as YopM308, possess 
membrane translocation properties along with immunomodulatory functions. Harnessing effector 
proteins with dual penetrating and therapeutic functionality is interesting and contrary to the 
normal reductionist approach science has taken with penetrating peptides and single chain 
antibody fragments. Desolvating these dual functioning effectors into protein nanoparticles can 




YopM can be adsorb onto the surface of nanoparticles. There are many yet-to-be discovered 
bacteria with useful evolution-optimized functions. CRISPR highlights how studying bacterial 
defense and survival mechanisms can inspire new tools for engineers to solve societal problems. 
 
5.2.2 Combinatory therapeutics  
The protein nanoparticle platform allows for incorporation of multiple therapeutic 
proteins. The alginate/chitosan microparticle platform also allows for incorporation of multiple 
therapeutics such as nanoparticles, nucleic acids, small molecules, cells, and probiotics. Being 
able to treat diseases by multiple modes of action can potentially provide some of the most 
potent drugs. For example, Lewis and Keselowsky utilize dual microparticles, large 
microparticles that cannot be internalized that deliver extracellular components to bind cell 
surface receptors and the small microparticles can be internalized to deliver intracellular 
components. They have used this strategy to treat diabetes309 and suppress inflammation310 and 
have started multiple companies using this approach to tackle different diseases. Protein 
nanoparticles and alginate/chitosan microparticles can provide a similar platform for 
combinatory drug delivery.  
Effector enzymes, such as AvrA, can block the signaling pathways leading to cytokine 
production and siRNAs can prevent mRNA coding inflammatory cytokines from being 
translated into proteins. This presents a highly potent therapeutic that combats inflammation via 
two independent mechanisms. Their delivery challenges are similar as they must both access the 
cytosol while avoiding degradation and clearance. They could potentially be encapsulated in a 
single protein nanoparticle through siRNA forming electrostatic complexes with soluble protein 




nanoparticle, if successful, can loaded into alginate/chitosan microparticles with anti-
inflammatory small molecule drugs and/or probiotics to restore healthy immunological activity. 
This is an extreme example, however, highlights the possibility and attractiveness of 
combinatory therapies. 
Another interesting direction for alginate/chitosan microparticle is oral vaccination. 
Recently, a protein nanoparticle formulations made of conserved influenza viral proteins were 
shown to be effective in inducing broad protection indicating its potential to be a universal flu 
vaccine311. Encapsulating these nanoparticles in alginate/chitosan microparticles can provide an 
oral formulation for universal flu vaccine. Peyer’s patches function as immune centers in the 
intestines and the targets of oral vaccination312. We speculate in Chapter 3 that alginate/chitosan 
microparticles release nanoparticles much earlier in the gastrointestinal tract and this feature 
could be beneficially for oral vaccinations. Peyer’s patches are only found in the small intestines 
and also provides an access point to systemic delivery that bypass the liver, avoiding first pass 
effect166. Preliminary experiments can be done using current eGFP nanoparticles in 
alginate/chitosan microparticles, gavaging them into mice, harvesting the Peyer’s patches and 
staining for eGFP. This can motivate future studies to test oral vaccination and challenge studies.  
 
 
5.2.3 Colon-specific delivery  
Alginate/chitosan microparticles have an estimated 1% colonic delivery efficiency. This 
leaves large room for improvement. A common method of achieving colon specificity is utilizing 
polymethacrylate polymer coating, Eudragit. Other have manufactured similar microparticles on 
a large scale with Eudragit, through prilling to obtain a colon-targeted delivery system313. It is 




similar 1-step or 2-step method described in Chapter 3. Future work should explore the 
possibility of an additional alginate/chitosan microparticle coating with Eudragit and possibility 
switch to naturally-derived coatings such starch that also show similar colon-specific delivery314 
to follow with the themes of this thesis. 
 
 
5.2.4 Powderized formulations of alginate/chitosan microparticles  
Currently, the alginate/chitosan microparticles are stored in water. These microparticles 
are also stored in the fridge to preserve the activity of the encapsulated protein nanoparticles. 
Powderized or lyophilized formulations of these microparticles would provide long term storage 
not reliant on the cold-chain. This feature is highly desirable and would greatly increase the 
commercial potential of these microparticles. Powderized formulations can be compressed to 
form tablets or aerosolized to allow delivery into other non-invasive routes. Alginate and 
chitosan raw materials were purchased as powders that were dissolved in water to form droplets 
for nanoparticle encapsulation. Therefore, it seems plausible to repowderize these materials 
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